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Periodontitis is a multifactorial disease with microbial dental plaque as the etiological agent. The 
manifestation and progress of periodontitis is influenced by a wide variety of determinants and 
factors, including subject characteristics, social and behavioral factors, systemic factors, genetic 
factors, the microbial composition of dental plaque, and others. The pathogenesis of periodontal 
disease results in resorption of alveolar bone and loss of the attachment apparatus to the teeth. 
There is a biological potential that periodontal destruction may be influenced by systemic bone 
loss. Since alveolar bone loss is a prominent feature of periodontal disease, disturbances in bone 
mineral density (BMD), especially in the jaws, are suspected of being an aggravating factor in 
periodontal disease. In previously published research, the severity of osteoporosis may be related 
to tooth loss in post-menopausal women. Considering the relationship among bone mineral  
density, osteoporosis, and periodontitis in men, it is known that men completing androgen 
ablation therapy for control of prostate cancer are at higher risk for osteoporosis. As androgen 
deprivation therapy is the recommended treatment for men with metastatic or locally-advanced 
nonmetastatic prostate carcinoma, and as prostate carcinoma is the most common visceral 
malignancy and the second leading cause of death from cancer in men, the relationship between 
androgen deprivation therapy and loss of bone mineral density is a matter of public health 
importance. 
 This dissertation assesses the association between bone mineral density, the presence of 
periodontal disease, and the possible subsequent onset of clinical osteoporosis, as seen among a 
population of older women followed longitudinally; a set of men with prostate carcinoma 
undergoing androgen ablation therapy; and those men in the same set not receiving androgen 
ablation for prostate cancer. We believe our research, using the model of periodontal bone 
density and oral bone loss, shows additional clear empirical evidence pointing to a cause-and-
effect relationship between androgen deprivation therapy and loss of bone mineral density. 
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1.0 CHAPTER ONE: INTRODUCTORY REMARKS 
THE RELATIONSHIPS AMONG PERIODONTAL DISEASE, BONE LOSS, AND ANTI-ANDROGEN 
THERAPY, BY A CONSIDERATION OF THE EPIDEMIOLOGY AND ETIOLOGY OF PERIODONTAL 
DISEASE AND OSTEOPOROSIS: A REVIEW OF THE LITERATURE 
 
 
Periodontal disease is a local chronic inflammatory disease of the tooth-supporting tissues, characterized 
by inflammation of those tissues. The disease has a prevalence of thirty-five (35) percent in the adult 
population of the United States (Consensus Report Annals of Periodontology 1996; Consensus Report 
Journal of the American Dental Association 1998), and is a major cause of tooth loss and edentulism 
among adults. Periodontal destruction---pathologic inflammation of the gingival and hard tissues---often 
results in bone loss in the jaw, mobility of teeth, and ultimately tooth loss. The health and social impacts 
of periodontal disease are enormous and adversely influence nutrition, speech, oral function, and facial 
esthetics.  
 The pathogenesis of periodontal disease results in resorption of alveolar bone and loss of the 
attachment apparatus to the tooth. There is the biological potential that periodontal destruction may be 
influenced by systemic bone loss (Consensus Report Annals of Periodontology 1996). Since alveolar 
bone loss is a prominent feature of periodontal disease, disturbances in bone mineral density (BMD), 
especially in the jaws, are suspected of being an aggravating factor in the case of periodontal disease 
(Wactawski-Wende et al. 1996). 
 Our incomplete understanding of the role of various risk factors obscures the specific causes and 
underlying mechanisms of the periodontal disease process (Albandar 2002, Albandar 2002). Established 
risk factors for periodontal disease include dental plaque, calculus, smoking, systemic disease, stress, and 
genetic traits. It is clearly documented that the incidence of periodontal disease increases with advancing 
age. Significant age-demographic shifts exist in the United States populations and, as people live longer 
and retain more teeth, the number of people developing periodontal disease is expected to increase in the 
next few decades. Changes in our knowledge of the etiology of periodontal disease, and better recognition 
of the potential importance of the susceptibility factors as they affect the initiation and progression of 
periodontal disease, have led to an intense study of specific risk factors for periodontal disease. 
 Several convincing epidemiologic studies, such as the surveys conducted by the National Center 
for Health Statistics (Ronderos 2004) and those of the National Institute of Dental and Craniofacial 
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Research (NIDCR), with additional studies from abroad, have challenged the popular perception that 
humans have a universal susceptibility to periodontal disease (Irfan 2001). 
 The relationship of osteoporosis in men and periodontal disease due to androgen ablution is not 
well established. Studies to evaluate the relationship between osteoporosis due to androgen ablution and 
periodontal disease are essential for enhancing our understanding of systemic bone pathogenesis. The 
objective of this research is to assess, and thus better understand, the association between bone mineral 
density, the presence of periodontal disease, and the possible subsequent onset of clinical osteoporosis, as 
seen among a set of men with prostate carcinoma undergoing androgen ablation therapy, and those in the 
same set not receiving androgen ablation for control of prostate cancer.  
 
 
 
1.1 THE ETIOLOGY AND EPIDEMIOLOGY OF PERIODONTAL DISEASE 
 
 
Periodontal disease is a pathological condition, a chronic inflammatory disease, affecting the supporting 
structures of teeth, characterized by inflammation of the teeth-supporting tissues at the gums. Periodontal 
disease is identified by a bacterial challenge that can destroy the host tissues, the response leading to 
periodontal attachment loss, bone loss, and ultimately possible tooth loss (Nunn 2003; Consensus Report 
Annals of Periodontology 1996; Journal of the American Dental Association 1998). 
 Thus, periodontitis is clearly a multi-factorial disease with microbial dental plaque as the initiator 
(Nunn 2003; Consensus Report Annals of Periodontology 1996; Journal of the American Dental 
Association 1998). However, the manifestation and progression of periodontitis is influenced by a wide 
variety of determinants and risk factors, including subject characteristics, social and behavioral factors, 
systemic factors, genetic factors, the microbial composition of dental plaque, and others (Nunn 2003; 
Annals of Periodontology 1996; Journal of the American Dental Association 1998). If periodontitis is not 
treated, the disease will slowly progress and painlessly destroy the bone which supports the teeth. 
Untreated, the disease will eventually cause tooth loss. 
 
1.1.1 The epidemiology of periodontal disease: Prevalence and incidence 
Although many epidemiological studies have been conducted concerning periodontal disease using the 
parameters of clinical attachment level, attachment loss, probing pocket depth, and gingival recession, the 
evidence pertaining to prevalence, incidence, and risk factors in an older adult population of either sex is 
limited (Albandar 2002). 
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 The NHANES III (1994) study showed that among dentate adults in the United States (six teeth 
or more present) age 30 and older, 3.1 percent had advanced periodontitis (defined as pocket depth upon 
probing greater than 6mm); 9.5 percent had moderate periodontitis (defined as pocket depth upon probing 
4-6 mm), 21.8 percent had mild periodontitis (defined as pocket depth upon probing 3-5 mm) and 65.5 
percent had no periodontitis (defined as pocket depth less than 3 mm). The prevalence of periodontitis (all 
severities) increases steadily with increasing age (Albandar 2002, Albandar 2002). Using the measure of 
tooth loss to definitively diagnose periodontitis in his six-year study, the youngest age group (18-33) 
presented at baseline with the fewest mean number of teeth lost (1) and concluded with the least (0). 
Subjects over age 57 entered with the most teeth lost (3.6), and concluded with the most teeth lost (0.4).   
 Periodontal disease and aging are commonly thought to be correlated with each other. The 
relationship is intuitively thought to be more related to the breakdown of the periodontal tissues over 
time, rather than an actual function of the accumulation of chronological years causing a deficiency that 
increases the individual’s susceptibility to periodontal disease (Nunn 2003; Genco 1996). 
Epidemiological studies have shown more periodontal disease, both in terms of attachment loss as well as 
bone loss, among older age groups than younger age groups (Grossi et al. 1994; Grossi et al. 1995; 
Streckfus et al. 1999). Other research has shown that certain physiological changes in the periodontium 
occur with age (Johnson et al. 1989 and van der Velden 1984) although these physiological changes 
alone are not responsible for the breakdown in the gingival tissues (the gingival recession, the attachment 
loss, the eventual tooth loss). 
 Pocket probing depth is the measure from the free gingival margin (FGM) to the base of the 
sulcus/pocket with the use of a calibrated probe (HuFriedy Michigan 0 probe, diameter of probe is 0.5 
mm). Pocket depth is probed on six sites per tooth (distobuccal, midbuccal, mesiobuccal, distolingual, 
midlingual, and mesiolingual). Clinical periodontal attachment level and the loss of periodontal 
attachment are defined as the distance in millimeters (mm) from the cementoenamel junction (CEJ) to the 
base of the pocket. Probing depth is the distance from the free gingival margin (FGM) to the base of the 
sulcus/pocket. Other essential periodontal measures are the presence or absence of gingival recession or 
gingival bleeding, and the measures of supragingival plaque and calculus. Gingival bleeding will be 
measured as (0: no bleeding; 1: bleeding); supragingival plaque will be measured as (0: no plaque; 1: 
plaque). Calculus will be measured as (0: no calculus; 1: supragingival calculus). 
 Among adult Americans, males have a greater prevalence of periodontitis than females. Albandar 
(2000) reports that different racial and ethnic groups within a given population show marked differences 
in periodontal disease indicators, and the general diagnosis of periodontitis. An important finding of the 
NHANES I study was the trend that African-Americans in the U.S. population have a much higher 
occurrence of periodontitis than Caucasians (1.28 to 0.76 respectively, using the general indicator of 
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Periodontal Index) and a higher prevalence of periodontitis than Mexican-Americans. Non-Hispanic 
whites had significantly less periodontitis than either of the other two racial groups (Albandar 2002). The 
same ratios were confirmed in Albandar’s 2002 study of periodontitis among 14,000 U.S. adolescents 
(13-17 years old): early onset forms of periodontitis occurred in 10 percent of the adolescent African-
Americans, five percent of Hispanics, and 1.3 percent of whites. This gives a prevalence ratio of 7.7 for 
African-American adolescents, and 3.9 percent for Hispanic adolescents, compared to the white 
adolescents.   
 Nunn (2003) points out that race as a risk factor for periodontitis is a complex issue. She notes 
that Prevotella intermedia presents a risk factor for blacks, but not for whites. When socioeconomic risk 
factors for periodontitis were not considered, blacks were three times more likely than whites to exhibit 
advanced periodontal destruction. When subjects were in the same socioeconomic status, differences in 
gum disease often disappeared. 
 Albandar (2002) takes the conclusions of the NHANES III data regarding gender, race and 
ethnicity, and the common variables indicating periodontal disease, and presents this data regarding 
prevalence rate ratios (duplicated here as Table 1, next page). In the U.S., adult blacks show the highest 
prevalence of periodontitis and the most loss of periodontal tissue, followed by Mexican-Americans. 
Whites show the least disease and tissue loss. As shown in the table, blacks have a much higher 
probability of having attachment loss and increased probing depth, and Mexican-Americans have a 
moderately increased probability, compared to whites. For attachment loss ≥3mm, the ratio was 1.26 for 
blacks, and 1.10 for Mexican-Americans, whereas for attachment loss of ≥5mm, the ratio was 1.73 and 
1.28, respectively. Hence, in the U.S. adult population, the probabilities of having attachment loss of 
≥3mm and ≥5mm, respectively, were 26 percent and 73 percent higher for blacks and 10% and 28% 
higher for Mexican-Americans compared to whites. A similar pattern was observed for the other 
periodontal disease indicators, and is also summarized in Table 1. 
 
1.1.2 The epidemiology of periodontal disease: Periodontal attachment loss 
Attachment loss is highly prevalent in the U.S adult population, with more than half (53.1 percent) of 
subjects 30 years and older showing one or more teeth with 3mm and greater attachment loss, and 32.7 
percent of subjects showing 4mm and greater attachment loss (Nunn 2003). The prevalence and extent of 
attachment loss increased steadily with increasing age, and both parameters were significantly higher in 
males than in females, and higher in black and Mexican-American individuals than among white subjects 
(again, see Albandar’s data in Table 1). In one research report, taking into account different age groups, 
the distribution of the periodontal disease indicators across the dentist’s jaw sextants showed that 
attachment loss affected most frequently the mandibular incisors and the maxillary molars (Spalj 2003). 
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 Table 1.1 Prevalence rate ratios of periodontal variables, by gender and race-ethnicity  
[Data show males v.females (blacks v.whites, and Mexican-Americans v.whites) 30 years and older examined
in the third National Health and Nutrition Examination Survey (NHANES III) U.S. 1988-1994] 
 
Gender Race-Ethnicity Variable 
Males/females Blacks/whites Mexican-
Americans/whites 
Prevalence (percent of persons) 
Attachment loss ≥3mm 1.23 1.26 1.10 
Attachment loss ≥4mm 1.44 1.46 1.22 
Attachment loss ≥5mm 1.55 1.73 1.28 
Probing depth ≥3mm 1.14 1.24 1.22 
Probing depth ≥4mm 1.46 1.97 1.61 
Probing depth ≥5mm 1.73 2.71 1.79 
Gingival bleeding 1.17 1.15 1.31 
Gingival recession ≥1mm 1.12 1.03 0.94 
Gingival recession ≥3mm 1.54 1.29 1.09 
Dental calculus 1.02 1.05 1.06 
Extent (percent of teeth per person) 
Attachment loss ≥3mm 1.48 1.54 1.17 
Attachment loss ≥4mm 1.65 1.75 1.24 
Attachment loss ≥5mm 1.93 2.06 1.33 
Probing depth ≥3mm 1.39 1.79 1.48 
Probing depth ≥4mm 1.63 2.47 1.65 
Probing depth ≥5mm 2.00 3.31 1.85 
Gingival bleeding 1.24 1.31 1.53 
Gingival recession ≥1mm 1.30 1.13 0.95 
Gingival recession ≥3mm 1.67 1.49 1.13 
Dental calculus 1.21 1.49 1.35 
[Data compiled by Albandar et al. in 2000] 
 
1.1.3 The epidemiology of periodontal disease: Probing pocket depth 
Sixty-four percent of U.S. adults in this study had one or more teeth with a probing depth of 3 mm or 
greater (mild periodontitis). Approximately 22.3 percent had a probing depth of 4mm or greater 
(moderate periodontitis). The prevalence of probing depth at 4mm and greater increased steadily with 
age. The prevalence and extent of probing depth at 4mm and more was significantly greater among males 
than in females and among blacks and Mexican–American than whites. Blacks had the highest probing 
depth measurement among the three race-ethnicity groups (Consensus Report Annals of Periodontology 
1996; Journal of the American Dental Association 1998).  
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 Again, Albandar’s data best summarizes all of these periodontal disease indicators---attachment 
loss, probing depth, gingival bleeding, gingival recession, and dental calculus---related to gender and race 
and ethnicity (Table 1.1). 
 
1.1.4 The epidemiology of periodontal disease: Gingival recession 
In the same study, 22.5 percent of the subjects had gingival recession at 3mm and greater. The prevalence 
and extent of gingival recession also increased steadily with increasing age: 10 percent of subjects 30-39 
years old and 60 percent of subjects 80-90 years old had one or more teeth with 3mm gingival recession. 
Males had a significantly greater prevalence and extent of gingival recession than females. The 
prevalence and extent of gingival recession were comparable in the three race ethnic groups (Consensus 
Report Annals of Periodontology 1996). 
 
1.1.5 The etiology of periodontal disease: Summary and risk factors 
Clinicians have long believed they had a profile of the patient with periodontal disease, but reviewing the 
literature regarding the etiology of periodontitis shows little hard evidence to identify the assumed 
specific predisposing factors (Rees 2003). The profile, according to Rees, includes a patient who is a 
smoker, is emotionally stressed, possibly malnourished, prone to disease, has a family history of 
periodontitis, possesses local factors predisposing to the accumulation of plaque (clinically recognizable 
in short, again, as a smoker with poor oral hygiene) and basically not motivated and not compliant with 
the oral hygiene maintenance protocols (brushing, flossing, recalls every three, six---at most---twelve, 
months) and not good at oral hygiene when brushing or flossing is undertaken. 
 While the profile is clinically valid, the risk factors are more profound than the profile indicates, 
and detailed, thorough, examination of the underlying risk factors---the systemic risk factors---is 
warranted and necessary. All persons are not equally susceptible to periodontal disease and do not 
respond equally well to periodontal therapy. In a classic longitudinal study of a population with no access 
to dental care and poor oral hygiene (Albandar 1990), enormous variability among individuals in the rates 
of periodontal disease progression was observed. In this mostly homogenous population, some persons 
developed disease at very rapid rates, while others had little or no disease progression (Albandar 1990). 
Again, the established risk factors for periodontal disease are dental plaque, calculus (a hard mineral 
deposit produced by the action of bacteria and body calcium, requiring removal with instruments by a 
professional), smoking, systemic disease, age, genetic traits, stress, and others. While each of these 
factors alone may have a detrimental effect on etiology, prognosis, and treatment outcomes, it should be 
kept in mind that the presence of any of these factors alone or in combination may influence yet a 
different outcome (Journal of the American Dental Association 1998).  
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 While it is true that some strong current epidemiologic research has challenged the notion that 
humans face a universal susceptibility to periodontal disease, it is also true that between five and twenty 
percent of the population have severe forms of periodontal disease. The etiology of chronic adult 
periodontitis is bacterial in nature, involving pathogens such as Actinobacillus actinomycetmcomitans, 
Porphyromonas gingivalis, and Bacteroides forsythus. Current concepts in the etiology of periodontal 
disease emphasize systemic factors which may place patients at risk to develop periodontitis. Conversely, 
periodontitis may be a risk factor in the development of a variety of systemic conditions. A clearer 
understanding of the relationship between oral health and systemic disease will aid healthcare providers in 
the management of a variety of conditions and earlier detection and preventive strategies may be 
developed to address potential systemic problems. A brief closer look at the most current information 
regarding the association between periodontal disease and the chief systemic risk factors of smoking, 
diabetes mellitus, obesity, atherosclerosis, hormone replacement therapy, and osteoporosis is worthwhile 
at this point. We will conclude the risk factor discussion of osteoporosis by transiting into an in-depth 
look at osteoporosis in men, and then beginning the discussion of our research interest, the relationships 
between periodontal disease, bone loss and anti-androgen therapy. 
 
1.1.6 The risk factors for periodontal disease: Smoking  
Periodontal disease long has been associated with smoking. Although smokers do have greater levels of 
plaque and calculus than nonsmokers, these factors alone cannot account for the increased incidence of 
periodontal disease. S.G. Grossi and colleagues found a direct linear relationship between the level of 
smoking (pack years) and destructive periodontitis even after adjusting for confounding variables such as 
age, oral hygiene, gender, and socioeconomic status (Grossi et al. 1995). Smoking was shown to be a 
strong risk indicator for periodontal disease, with an odds ratio of 2.0 to 5.0 when evaluating connective 
tissue attachment loss and 1.5 to 7.0 when measuring bone loss. Zambon and Grossi (1996) further 
directly concluded that cigarette smoking increased the risk for periodontitis, by increasing the risk for 
subgingival infection with periodontal pathogens. In other research, Grossi evaluated the effects of 
smoking and not smoking on healing after mechanical forms of periodontal therapy, such as scaling and 
root planing (1997) and has also investigated the independent responses of smokers and diabetics to 
periodontal therapy (1996). Smoking is a major risk factor for destructive periodontal disease and should 
be addressed when evaluating each patient, regardless of the individual’s gender, age, or other risk 
factors. This deleterious relationship between smoking and periodontal disease is seen in smokers 
regardless of their overall levels of plaque accumulation. However, the specific microbial flora in smokers 
may shift to a more pathogenic profile (Van Winkelhoff 2001). There are conflicting reports regarding the 
effects of smoke on the qualitative and quantitative composition of periodontal pathogens. Recent reports 
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have shown that the rate of recovery of such harmful pathogens from relatively shallow pockets is greater 
in smokers (Egger 2001). These finding suggest that tobacco smoking itself may promote the 
development of local environments that favor the growth of such pathogenic species. Tobacco products 
may also exert a destructive effect on the periodontium by impairing the normal defense of the host 
response, or by stimulating the destructive effects of the host response (Person 2001). 
 
1.1.7 The risk factors for periodontal disease: Drinking alcohol  
In her comprehensive discussion of the etiology of periodontitis (2003), on discussing the risk factors, 
Nunn (citing Tezal 2001) summarizes the risk factor of alcohol consumption, concluding that excessive 
alcohol consumption has been associated with an increased risk of clinical attachment loss as well as an 
increased risk of gingival bleeding. However, no association between alcohol consumption and alveolar 
bone loss has been found (Nunn 2003, Tezal 2001). 
 
1.1.8 The risk factors for periodontal disease: Diabetes 
The severity of diabetes mellitus (Type I) or non insulin-dependent diabetes mellitus (Type II) is related 
to the incidence and severity of periodontal disease (Cianciola 1982; Shlossman 1990). Synthesis of 
collagen appears to be affected by glucose levels. Gingival fibroblasts from diabetic patients synthesize 
less collagen compared to non-diabetic subjects (Willenshausen-Zonnchen 1991). In addition to finding 
decreased collagen production in association with diabetes, investigators have found increased crevicular 
fluid in diabetic patients. The increased crevicular fluid collagenase activity appears to be primarily of 
neutrophil origin. Interestingly, the increased crevicular fluid collagenase levels found in patients with 
diabetes can be inhibited in vitro by tetracycline (Sorsa 1991). Collagen in a hyperglycemic environment 
undergoes non-enzymatic glycosylation and cross-linking between the collagen molecules. This collagen 
cross-linking significantly contributes to reduced solubility and decreases turnover rates. Consistent with 
this, diabetic gingival collagen shows decreased solubility. Significantly, a return to near-normal 
solubility of collagen can be achieved by insulin treatment (Sorsa 1991). Also defects in PMN function; 
induction of insulin resistance (or increased insulin resistance in the diabetic subject); and vascular 
changes can all contribute to increased susceptibility to infection. Importantly, control of serum glucose 
levels appears to partly reverse these factors and should therefore be closely monitored with infections. 
 
1.1.8.1 Insulin–Dependent Diabetes Mellitus (Type I)  
In initial studies to investigate a relation between periodontal disease and insulin-dependent diabetes 
mellitus (Type I), the periodontal status of 263 patients was compared to 59 non-diabetics (Cianciola 
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1982). No periodontal disease was found among subjects under the age of 12, while 13.6 percent of 
individuals 13- to 18-years-old had periodontal disease. Individuals from 19- to 32-years-old had a 
prevalence of 39 percent. Investigators noted the duration of diabetes was greater in groups with severe 
periodontal disease. Thus, it appears that individuals with insulin-dependent diabetes mellitus (Type I 
diabetes) have an increased risk for developing periodontal disease with age, and the severity of 
periodontal disease increases with the increased duration of the diabetes. 
 
1.1.8.2 Non-Insulin-Dependent Diabetes Mellitus (Type II diabetes) 
Research conducted among Native American communities of (North American) Pima Indians, a 
population with an extremely high prevalence of non-insulin-dependent diabetes (Type II diabetes), has 
correlated the relationship of periodontal disease and diabetes. The initial study of periodontal disease in 
this community [(Nelson 1990) a cross- sectional analysis diagnosing periodontal disease by periodontal 
attachment loss (tooth loss) and percentage of interproximal crestal alveolar bone loss determined by 
panoramic radiograph], determined that the rate of periodontal disease in subjects with diabetes was 2.6 
times that seen in subjects without diabetes. Regardless of age or gender, subjects with diabetes had a 
higher prevalence of periodontal disease, indicating that diabetes is a risk factor for periodontal disease. 
 Further studies among the population showed individuals with non-insulin-dependent diabetes 
mellitus (Type II diabetes) to be 2.8 times more likely to have periodontal disease defined by clinical 
attachment loss, and 3.4 times more likely to have periodontal disease defined by radiographic bone loss. 
The increased risk of developing periodontal disease could not be explained on the basis of age, sex, or 
hygiene (Emrich Scholossman Genco 1991). A review of the literature on the relationship between 
periodontitis and diabetes by Soskolne a decade later (1998) reiterated the likelihood of the relationship, 
and considered the influence of periodontal disease on the control of the diabetic state, confirming the 
clinical observation that effective control of periodontal infection in patients with diabetes reduces the 
level of advanced glycosylation end products in the serum. Soskolne concluded that periodontal infection 
control must be considered an integral part of diabetic control. 
 Diabetes mellitus Type II and periodontitis are both common diseases in the United States. 
Many studies have established the clinical observation that periodontal disease may be more severe in 
patients with diabetes. In fact, periodontal disease has been referred to as the sixth most significant 
complication of diabetes Type II. Uncontrolled diabetics may present with multiple or frequent 
periodontal abscesses, generalized gingival swelling and bleeding, and advanced bone loss. It is possible 
that the increased severity of periodontitis in this population may be related to increased susceptibility, 
impaired host response, and excessive collagenolytic activity. Periodontal healing may be compromised 
in poorly controlled diabetics; however, patients who are well-controlled seem to respond as well as non-
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diabetics. Diabetic control may be negatively influenced by the presence of chronic infections, such as 
periodontitis, and treatment of a diabetic patient's periodontal condition may result in more favorable 
diabetic status. It is important to recognize periodontal disease as an indicator of a potential underlying 
systemic condition, such as diabetes mellitus, and consider periodontal health as an important component 
in the treatment of diabetic patients (Cianciola 1982; Shlossman and Genco 1990; Pucher 2004). 
 
1.1.9 The risk factors for periodontal disease: Obesity 
The growing prevalence of increased body weight and obesity in the United States has raised significant 
public health concerns (Mokdad et al., writing in the Journal of the American Medical Association 1999; 
also the American Journal of Public Health (2004) editorializing obesity as ‘the public health challenge 
of our time’). Obesity is implicated as a risk factor for several chronic health conditions, is associated 
with increased mortality, and, moreover, exists in complexes of multiple, clustered, behavioral risk 
factors. Identified by one group of authors (Fine et al. 2004) as among the four most common risk factors 
contributing to chronic disease [cigarette smoking, risky drinking of alcoholic beverages, physical 
inactivity, and overweight] and applied to the 2001 National Health Interview Survey, showed that 
seventeen percent of 29,000 subjects had three or more risk factors for chronic disease. The number of 
obese people is increasing rapidly in both western and eastern countries [James and others (2001) the 
report of the International Obesity Task Force (London), analyzing cross-cultural standards of acceptable 
body mass index, reported in Obesity Research]. The health implications of obesity when viewed in 
conjunction with raised cholesterol and hypertension is cited as the major cause of mortality and disease 
in Europe (same authors 2004). Obesity is further seen as an issue for developing countries (Caballero 
2001) and a review of the literature indicates analyses of the nature of obesity in South Africa, Pakistan, 
Brazil, China, Mexico, Australia, Gibraltar, Cyprus, Spain, and Greece; among Singaporean Chinese 
children, French and Italian children, black Jamaican children, postmenopausal Japanese women; and 
among twenty years of British children.  
 A 1998 report in The New England Journal of Medicine finds a relation between obesity and 
periodontitis in a healthy Japanese population (Saito Shimazaki Sakamoto). Investigating that relationship 
is further explored by al-Zahrani and colleagues of Case Western Reserve University (2003), who 
examined the link between body weight and periodontal disease using data from the third National Health 
and Nutrition Examination Survey (NHANES III).  
 A ten-year-old Swedish study concludes that counseling on a balanced diet and smoking 
cessation by dental professionals might possibly generally improve risk factors for cardiovascular disease 
(Johansson et al.1994). Adipocytes in the adipose tissues of obese people produce quantities of 
biologically active molecules such as leptin, an important molecule regulating energy expenditure and 
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body weight. Adipocyte-derived active molecules---adipocytokines---are candidate molecules accounting 
for the close association between obesity and other multiple risk factor syndromes. 
 The proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) is produced by 
adipocytes, and its blood concentration is elevated in obese patients and declines with weight loss. Studies 
have demonstrated that TNF-alpha suppresses insulin action via its specific receptor; hence, TNF-alpha 
exacerbates insulin resistance. TNF-alpha produced by adipose tissues of obese patients acts as a risk 
factor for periodontal inflammation, and TNF-alpha produced due to periodontal inflammation may be an 
additional important factor influencing insulin sensitivity in both obese and Type II diabetes patients. This 
interaction is a possible mechanism accounting for the two-way relationship between Type II diabetes and 
periodontal disease (Nishimura and Murayama 2001; Nishimura et al. 2003). 
 
1.1.10 The risk factors for periodontal disease: Atherosclerosis  
Atherosclerosis is a progressive disease involving large-to-medium-size muscular and large elastic 
arteries. The advanced lesion or atheroma consists of elevated focal intimal plaques with a necrotic 
central core containing lysed cells, cholesterol ether crystals, lipid-laden foam cells, and surface plasma 
proteins including fibrin and fibrinogen. The presence of an atheroma provides a surface for enhanced 
platelet aggregation and thrombus formation. According to data compiled by the American Heart 
Association, nearly one of every two Americans dies of cardiovascular disease that is attributed to 
complications of atherosclerosis manifested as coronary thrombosis and myocardial infarction (Kuller 
1988; Consigny 1995).  
 Periodontitis patients and coronary heart disease patients have a number of common 
characteristics, including variables such as age (positive correlation), education (negative association), 
gender (males higher), finances (negative association), tobacco use (positive correlation), alcohol use 
(positive correlation), hypertension (positive association), stress (positive association), and social 
isolation (positive association). Many studies have suggested a relationship between periodontitis and 
heart disease (Genco 2002). It is believed that, once established, periodontitis provides a biological 
burden of endotoxin (lipopolysaccharide) and inflammatory cytokines (especially IL-lß, PGE2, and TNF-
a) which initiate and exacerbate atherogenesis and thromboembolic events.  
 Odds ratios comparing systemic or periodontal bone loss and coronary heart disease, adjusted 
for age and other established cardiac risk factors, are reported to be 1.4 for all coronary heart diseases; 1.6 
for fatal coronary heart disease; and 2.0 for stroke. Major research endeavours [the Oral Infections and 
Vascular Disease Epidemiology Study (Desvarieux and others 2003) and the Atherosclerosis Risk in 
Communities Study (Beck and others from the University of North Carolina 2001; Slade and others 
2003)] are currently underway that will ultimately improve our understanding of the relationship between 
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periodontal disease and cardiovascular disease. The relationship of periodontal disease to cardiovascular 
disease was also the subject of a symposium by the American Dental Association in 2001 (Ciancio 2002). 
 
1.1.11 The risk factors for periodontal disease: Osteoporosis 
Osteopenia is a reduction in bone mass due to an imbalance between bone resorption and formation, 
favoring resorption, and resulting in demineralization of bone and osteoporosis. Osteoporosis is a disease 
characterized by a low bone mass and fragility and a consequent increase in the risk for fracture 
(Wactawski-Wende et al. 1996). Periodontal disease is characterized by resorption of alveolar bone and 
loss of connective tissue attachment. The bacterial etiology of periodontal disease is well established; 
however, loss of oral bone may be important in the creation of a susceptible host. The strongest 
associations between osteopenia and periodontal disease are found when evaluating hard-tissue 
measurements, such as bone mineral density, and measures of loss of oral bone, such as alveolar crest 
height, residual ridge resorption, and tooth loss (Jeffcoat 1998). Women with osteoporosis demonstrate 
greater attachment loss and reduced bone density in the mandible. Measurements of mandibular bone 
density appear to correlate well with systemic bone density. 
 Weyant and others in 1999, in a cross-sectional study, assessed the association between systemic 
bone mineral density and the clinical measurement of attachment loss in a group of 292 elderly dentate 
women with a mean age of 75.5 years. The results showed that, after controlling for age, smoking, and the 
number of remaining teeth, no statistically significant associations were disclosed between five indicators 
of periodontal disease and systemic bone mineral density. 
 Tezal and Wactawski-Wende in 2000 examined seventy postmenopausal Caucasian women with 
a mean age of 62 years, and found a significant association between interproximal alveolar bone loss and 
systemic bone mineral density. However, their data also showed a weak and statistically insignificant 
association between clinical attachment loss and systemic bone mineral density. 
 As we have already established, osteoporosis and periodontitis affect a large portion of the 
population. It has been hypothesized that osteoporotic persons are at increased risk for developing 
periodontitis. The role of osteoporosis in the etiology of periodontal disease is not fully understood. In 
some patients, there is a correlation between a decrease of mandibular bone mass and tooth loss (Mattson 
2002). While some reports suggest the lack of a significant association between periodontitis and 
systemic bone mass (Chestnut 2001), most observational studies support the possible role of low skeletal 
bone mineral density as a risk indicator for periodontitis (Jeffcoat 1998 and 2000; Reddy 2002; Tezal 
2000; Wactawski-Wende and others 1996; Elders 1992). Ronderos (2000), analyzing the NHANES III 
data, found that in women with high dental calculus scores, the mean clinical attachment loss per person 
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was higher in women with low compared to normal femoral bone mineral density. Meanwhile, no 
difference was found when the same comparison was made in women with low or moderate calculus 
scores. The clear interaction between calculus and bone mineral density suggests that, in the presence of 
the local irritant (the calculus), osteoporosis and, to a lesser extent, osteopenia, increase the risk for 
periodontitis present among osteoporotic and osteopenic persons, and that this risk may be prevented or 
attenuated by frequent calculus removal. Further (speaking to the risk factor next under discussion), 
Ronderos found that postmenopausal women who reported having used estrogen replacement therapy had 
significantly less attachment loss than those who had never used estrogen. 
 As we pointed out earlier, since alveolar bone loss is a prominent feature of periodontal disease, 
disturbances in bone metabolism density (BMD), especially in the jaws, are suspected of being an 
aggravating factor in the case of periodontal disease (Wactawski-Wende et al. 1996).  
 
1.1.12 The risk factors for periodontal disease: Hormone replacement therapy 
Since estrogen depletion is an important risk factor for the development of osteoporosis, it is critical to 
consider the role of estrogen as a possible underlying cause for the association between periodontitis and 
low skeletal bone mineral density (Pacifici 1996). In postmenopausal women, estrogen supplementation 
prevents loss of skeletal and alveolar bone mineral density and may be protective against gingival 
inflammation (Reinhardt et al. 1999) and attachment loss. The effect of steroid hormones as metabolic 
mediators on the expression of cytokines may be a plausible explanation for the protective effect of 
estrogen supplementation against bone loss, infectious disease, and periodontitis (Pacifici 1996; Reinhardt 
et al. 1999). It is possible that hormone replacement therapy, calcium, Vitamin D supplementation, and 
other medications used to prevent low bone density have positive effects on the outcome of periodontal 
therapy (Orwoll et al. 1990; Simon 2002; Streckfus et al. 1997). 
 The sum of these studies suggests that women with osteoporosis and poor oral hygiene are at a 
higher risk for attachment loss than women without osteoporosis, or osteoporotic women with good oral 
hygiene. Further, the data suggest that this general risk may be attenuated by the use of estrogen 
replacement therapy. However, given the reported risks of estrogen replacement therapy to other body 
systems, and the fact that the magnitude of the increase in risk is not established, without further 
longitudinal research it is not possible to justify intervention with hormone replacement therapy for the 
purpose of modulating tooth attachment loss (Albandar 2002). 
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1.2 THE EPIDEMIOLOGY AND ETIOLOGY OF OSTEOPOROSIS, AND THE 
RELATIONSHIP BETWEEN SYSTEMIC BONE MINERAL DENSITY AND ORAL 
BONE MINERAL DENSITY 
 
 
1.2.1 Epidemiology of osteoporosis: Prevalence and incidence 
Osteoporosis, or porous bone, is characterized by reduced bone mass and structural deterioration of bone 
tissue, leading to abnormal bone architecture, fragility of bone, and increased risk of fragility fracture, 
particularly of the hip, spine, and wrist. Osteoporosis is a major public health threat for 44 million 
Americans, and approximately 1.5 million will suffer fragility fractures each year, including 300,000 hip 
fractures, approximately 700,000 vertebral fractures, 250,000 wrist fractures, and more than 300,000 
fractures at other sites. Ten million Americans already have osteoporosis, and 34 million more have low 
bone mass, placing them at risk for osteoporosis. Half of all women and one-quarter of men over 50 will 
have an osteoporosis-related bone fracture in their lifetimes.  
 The incidence of osteoporosis is estimated at twenty (20) percent of postmenopausal white 
women (Cummings and Melton 2002). An alternative approach to taking bone mass measurements is to 
use morphological deformities as the variable to define osteoporosis. When using defined vertebral 
deformities as the delimiting variable, the prevalence of osteoporosis fell to an average 12 percent in both 
men and women. Among women, rates ranged from five percent at age 50-54 years and rose to 18 percent 
at age 75-79 years (Cummings and Melton 2002). Among men the reported incidence of osteoporosis was 
10 percent at age 50-54 years, rising to 18 percent at age 75-79 years. Furthermore, the already-high 
prevalence of this silent disease is on the rise. Projections indicate a three-fold increase in osteoporosis 
hip fracture in men within ten years (Cummings and Melton 2002). The likelihood of suffering a hip 
fracture accelerates in the ten years following the menopause in women and takes off similarly after age 
70 in men.  
 Osteoporosis in men also has profound clinical implications (Seeman 1983, 1995, 1997). 
Osteoporosis is a significant health problem and contributor to disability and premature mortality among 
older men. Osteoporosis occurring in middle-aged and elderly men is commonly associated with alcohol 
abuse, smoking, immobilization, and medications. The incidence of hip fracture increases dramatically 
with age in both men and women, but the impact of hip fracture on mortality may actually be greater in 
men (Kenny Taxel 2000; Kenny Joseph Taxel 2003; Seeman) such that the number of fractures in men is 
nearing that observed several decades ago in women. Men suffer one-third of all hip fractures due to 
osteoporosis. More than two million American men suffer from osteoporosis, and millions more are at 
risk. Each year, 80,000 men suffer a hip fracture (among 300,000 reported annually) and one-third of 
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these men die within a year. Estimated national direct expenditures (hospitals and nursing homes) for 
osteoporosis and related fractures are $14 billion each year; men comprise one-third of all osteoporosis 
cases, and account for one-third of the national health care expense deriving from osteoporosis care. 
 
 
1.2.2 Etiology of osteoporosis 
Osteoporosis is characterized by low bone mass and micro-architectural deterioration with a consequent 
increase in bone fragility and susceptibility to fracture. According to the United Nations’ World Health 
Organization (Kanis 2002), osteoporosis is operationally defined when bone mineral density (BMD) is 
2.5 standard deviations (SD) or more below that which is the standard in the young normal individual. 
Osteopenia is defined as bone density levels between 1 SD and 2.5 SD below normal BMD (same; also 
Ahmed 1997) 
 Bone is a living, growing tissue. It is made mostly of collagen, a protein that provides a soft 
framework, and calcium phosphate, a mineral that adds strength and hardens the framework. This 
combination of collagen and calcium makes bones strong, yet flexible to withstand stress. More than 99 
percent of the body's calcium is contained in the bones and teeth. The remaining one percent is found in 
the blood. Throughout one’s lifetime, old bone is removed (resorption) and new bone is added to the 
skeleton (formation). During childhood and teenage years, new bone is added faster than old bone is 
removed. As a result, bones become larger, heavier, and denser. Bone formation continues at a pace faster 
than resorption until peak bone mass (maximum bone density and strength) is reached around age 30. 
After age 30, bone resorption slowly begins to exceed bone formation. 
 Osteoporosis develops when bone resorption and bone formation become uncoupled---that is, 
when rates of bone resorption exceed rates of bone formation. The bone mass attained during childhood is 
perhaps the most important determinant of life-long skeletal health. Achieving optimum bone mass early 
in life reduces the impact of bone loss related to aging. Genetic factors exert a strong influence upon peak 
bone mass, but controllable environmental and lifestyle factors also play a role. These include good 
nutrition, particularly adequate calcium and vitamin intake. Only ten percent of girls and 25 percent of 
boys between ages nine and seventeen obtain an adequate amount of calcium in their diet through the 
consumption of dairy products and vegetables. There is strong evidence that physical activity early in life 
contributes to higher peak bone mass. Osteoporosis is more likely to develop if one did not reach optimal 
bone mass during the bone building years. 
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1.2.3 Etiology of osteoporosis: Detection 
Osteoporosis is called the silent disease because bone loss occurs without symptoms. In fact, clinicians 
recognize no symptoms, except possibly back pain from a vertebral fracture. The bones become so weak 
that a sudden strain, bump, or fall causes a hip to fracture or a vertebra to collapse; a simple fall or lifting 
a heavy object may cause a vertebral fracture. It is collapsed vertebra that may initially be felt or seen in 
the form of severe back pain, loss of height, or spinal deformities such as kyphosis [literally, 
humpbacked], defined as abnormal backward curvature of the spine. 
 There have been dramatic advances in methods to diagnose osteoporosis and assess the risk of 
future fractures. Technology is now available to determine bone mass (or density) safely, conveniently, 
and at a relatively low cost in appendicular and axial skeletal sites with an accuracy exceeding 95 percent 
and a precision error less than one percent. Single photon absorptiometry (SPA) and single x-ray 
absorptiometry (SXA) are applicable to peripheral appendicular bones; dual x-ray absorptiometry (DXA) 
has largely replaced dual photon absorptiometry (DPA) as the optimum method to estimate axial, 
proximal appendicular, and total body mass. Quantitative computed tomography (QCT) has been adapted 
to bone densitometry, but limited accessibility and high cost have precluded the widespread routine use of 
quantitative computed tomography. Less expensive methods such as ultrasound, x-ray photodensitometry, 
and others remain to be validated in careful clinical studies. These clinical measurement methods used to 
assess bone mineral density are summarized in Table 1.2, on the next page. 
 Substantial evidence from prospective studies indicates that bone mass measurement is the most 
accurate available predictor of fracture risk (Black 2000). Measuring any site is probably equally 
predictive of the risk of all osteoporotic fractures, while measurement of the hip appears to be a better 
predictor of the risk of hip fracture (Delmas 2002). 
 Bone mineral density (BMD) tests measure bone density in the spine, wrist, or hip (the most 
common sites of fractures due to osteoporosis), while others measure bone in the heel or hand. These tests 
are painless, noninvasive, and safe. Bone density tests can detect low bone density before a fracture 
occurs; characterize the bone loss after a fracture has occurred; predict the individual’s likelihood of 
fracturing in the future; and determine the individual’s rate of bone loss, or monitor the effects of 
treatment, if the test is conducted comparatively with baseline data (Jeffcoat 1998; Jeffcoat Lewis Reddy 
Wang 2000). 
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 Table 1.2. Clinical measurement methods to assess bone mineral density 
 
 
Method    Sites    Units 
Single photon absorptiometry  Peripheral due to   Bone mineral content 
     need for water bath   g/cm 
          g/cm2 
Dual energy X-ray absorption Central or peripheral     Bone mineral density 
          areal density 
          g/cm2 
         Bone mineral content 
          in grams 
         refers to scanned area 
       Bone mineral apparent density 
g per approximation of volume 
Quantitative computed tomography Central or peripheral  Apparent bone density 
          mg/cm2 
 
1.2.4 Risk factors for osteoporosis 
Risk factors for osteoporosis can be divided into non-modifiable and modifiable risk factors. The non-
modifiable risk factors are gender (2:1 female to male); age (bones becomes less dense and weaker with 
age); early menopause; small or thin body frame; ethnicity (Caucasian and Asian women are at highest 
risk; African-American and Latino women have a lower but significant risk); and family history (people 
whose parents have a history of fractures also seem to have reduced bone mass and may be at risk for 
fractures) (Cummings Nevitt Browner 1995; Cummings and Melton 2003). 
 Risk factors that individuals can change are a lifetime diet lacking in calcium and Vitamin D; a 
lack of exercise, an inactive lifestyle, or extended bedrest; cigarette smoking and the excessive use of 
alcohol; anorexia; and levels of sex hormones off the norm [an abnormal absence of menstrual periods 
(amenorrhea), low estrogen level (menopause), and low testosterone level in men]. Low bone mass, 
certain medications (glucocorticoids or some anticonvulsants), the propensity to fall, and the presence of 
systemic disease such as hypothyroidism are modifiable to some extent (Cummings Nevitt Browner 1995; 
Cummings and Melton 2003). 
 Large cross sectional studies have found a strong inverse relation between bone mass and age. 
Results of early prospective studies of forearm bone loss in women suggested that the rate of bone loss 
decreases with increasing age. More recently, several longitudinal studies indicated that bone loss 
accelerates about 0.4-1.3 percent per year in the peripheral skeleton of men and women up to age 80 
(Greenspan Dresner-Pollak Parker London Ferguson 1997; Heyse 1993). 
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 Osteoporosis research has historically been focused on the disease in postmenopausal women. 
Although osteoporosis is less common in older men, the disease nonetheless represents a major health 
concern for men (above). The reason for the rising incidence of osteoporosis fractures in men is unclear, 
but the extension of the actual human life span, improvements in the quality of a long-lived-life, and 
better management of other chronic disease most likely play a role. At the present time, men over 50 
years of age have a 19-25 percent lifelong risk of any osteoporotic fracture (Seeman Melton O’Fallon 
Riggs 1983; other Seeman 1995, 1997, 2001). Testosterone is thought to be important in the development 
of peak bone mass but its role in age-related bone loss is not established.  
  
1.2.5 Risk factors for osteoporosis: Vitamin D deficiency  
Vitamin D intake is essential for maintenance of the skeleton throughout the lifespan, and often it is 
compromised in the elderly. Vitamin D is also derived from the conversion of precursors in the skin that 
are stimulated by sunlight. Decreased mobility and avoidance of the sun contribute to Vitamin D 
deficiency in the elderly. The skeletal effects of Vitamin D are two-fold: the vitamin ensures 
mineralization of the organic matrix of bone and the vitamin mediates mobilization of stored calcium and 
phosphate from bone to blood to achieve mineral homeostasis. Inadequate levels of Vitamin D produce a 
secondary increase in the release of parathyroid hormone that stimulates bone resorption and can result in 
osteoporosis (Simon LeBoff Wright Glowacki 2002).    
 
1.2.6 The relationship between systemic bone mineral density [BMD] and oral bone 
mineral density [BMD] 
Studies discussing the relationship between systemic bone mineral density (BMD) and oral bone mineral 
density (BMD) are summarized in Table 1.3. Most studies reported to date concerning this relationship 
are cross-sectional, using different populations and different methods to assess bone mineral density.  
 Kribbs and colleagues (1990, 1989, 1983, and Table 1.2) were the first to study the relationship 
between systemic bone mineral density and oral bone mineral density in both normal and osteoporotic 
women. Assessments of total body calcium were taken by neutron activation analysis, and found to be 
associated with mandibular density as measured by quantitative analysis of intra-oral radiographs. In a 
comparison of 85 individuals in two groups, the osteoporotic group had 20 percent less mandibular bone 
mass and density and a thinner cortex at the gonion than the normal group. The osteoporotic group also 
had a greater percentage of subjects who were edentulous.  
 Von Wowern and colleagues (1994) found less mandibular bone mineral content as measured by 
dual photon absorptiometry than in fourteen normal women. Streckfus and colleagues (1997) used 
quantitative measurements of vertical bitewing and hand radiographs in patients with active periodontitis.  
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The radiographs showed postmenopausal women on estrogen therapy had more alveolar bone loss, more 
missing teeth, and reduced alveolar and second metacarpal bone density than pre-menopausal women. 
Shrout and colleagues (2000) used morphologic measurements from digitized images of bitewing 
radiographs to correlate with lumbar and femoral bone mineral density in 45 post menopausal women 
who had no or only mild periodontal disease (no probing depths >5 mm). The complexity of the pattern of 
the trabecular bone weakly correlated with lumbar spine and femoral bone mineral density. 
 Most studies relate systemic bone mineral density with mandibular mineral density. In one study 
of both maxilla and the mandible (Southard 1992), forty-one dentate Caucasian women ages 20-78 were 
evaluated using quantitative intraoral radiography and systemic bone densities determined by dual energy 
x-ray absorptiometry (DXA). The density of maxillary alveolar process bone was significantly related to 
the density of the mandibular alveolar process, lumbar spine, hip, and radius in healthy women. The 
results also indicated that maxillary alveolar process bone density declined with age. 
 In a preliminary report of the oral ancillary study of the Women’s Health Initiative, 158 patients 
with a mean age of 62.2 years were evaluated (Jeffcoat 1998). Hip bone mineral density was measured by 
dual energy x-ray absorptiometry (DXA) and mandibular bone density by quantitative digital intraoral 
radiography. A significant correlation was found between mandibular basal bone and hipbone mineral 
density. 
 In summary, the collective data reported in most of these cross-sectional studies appears to 
indicate a relationship between systemic bone mineral density and oral bone mineral density, but the 
sample size on all of these studies was very small and only one investigator (Jeffcoat 1998) adjusted for 
age. Generally, most researchers used differing populations and did not adjust for the other co-variants 
such as smoking. The exception to this is Kribbs, studying both normal and osteoporotic women (1990), 
who showed 20 percent less mandibular density as measured by quantitative analysis of intra-oral 
radiographs. Additional data from ongoing longitudinal studies will further elaborate this relationship. 
All of the research discussed above and others is summarized in Table 1.3, next. 
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Table 1.3 Relationship between systemic bone mineral density (BMD) and oral bone mineral 
density (BMD) 
Authors  Population   Major Result   Type of study 
Jeffcoat et al. 158 postmenopausal  Significant correlation between Cross-sectional  
  women, ages 62.2±7.6 years  hip BMD and mandibular-basal  
      BMD 
Shrout et al. 45 postmenopausal women  Complexity of the trabecular   Cross-sectional 
  with no or mild periodontitis.  pattern weakly correlated with lumbar 
  Mean age 57.4 ± 5.8  spine and femoral BMD 
Southard et al. 41 dentate Caucasian women, Significant correlation between the Cross-sectional 
  ages 20 to 78 years   density of maxillary and mandibular 
      alveolar process, lumbar spine, hip,  
      and radius in healthy women. 
Streckfus et al. 28 healthy women, ages 23-78 Strong correlation between alveolar  Cross-sectional  
     bone and the second metacarpal  
      densities. Both reduced in post- 
      menopausal women. 
Jacobs et al. 69 women receiving HRT,   Correlation between spinal density Cross-sectional 
  aged 32-64 at entry   and mandibular bone mass at the  
      second examination (average follow-up 
      5.1 years) 
von Wowern  12 women with osteoporotic  Osteoporotic subjects had less bone Cross-sectional 
et al.  fractures    mineral content 
Kribbs   85 osteoporotic women and  Osteoporotic group had less   Cross-sectional 
  27 normal women, ages 50-85 mandibular bone mass and density 
Kribbs   85 osteoporotic women  Total body calcium, bone mass at Cross-sectional 
      radius, and bone density at spine    
     correlated with mandibular mass 
Kribbs et al.  50 normal women ages 20-90 Mandibular bone mass correlated Cross-sectional 
      with bone mass at spine and wrist 
Kribbs et al.  30 postmenopausal women Total bone calcium associated  Cross-sectional 
      with mandibular bone density 
Famili et al. 398 dentate women   Statistically significant relation Cross-sectional 
  (average age 75.5 years)   between tooth loss and  
      systemic BMD 
 
 
1.2.7 The relationship of periodontal disease and osteoporosis 
The relationship of tooth loss to bone mineral density has been studied. Several reports find a correlation 
between tooth losses and diminished systemic bone mineral density. Several mostly cross-sectional 
reports have used a variety of parameters to evaluate periodontal disease severity in subjects with 
decreased bone mineral density. These reports are summarized in Table 1.4, which examines the 
relationship of periodontal destruction and bone mineral density (BMD). The previous Table 1.3 examined 
the relationship between systemic bone mineral density (BMD) and oral bone mineral density (BMD). 
The next table, Table 1.4, examines the relationship between periodontal destruction and bone mineral 
density. 
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Table 1.4 Relationship of periodontal destruction and bone mineral density (BMD) 
Authors  Population   Major Result   Type of study 
Lundstron et al. 15 women with osteoporosis,  No statistically significant differences Cross-sectional  
  21 women with normal BMD  in gingival bleeding, probing pocket  
         depths, gingival recession, and  
           marginal bone level 
Taxel et al. 70 postmenopausal Caucasian Mean ABL significantly correlated  Cross-sectional 
  women aged 51-78   with BMD 
Weyant et al. 292 dentate women   No statistically significant relation Cross-sectional 
  (average age 75.5 years)   between periodontal disease and 
            systemic BMD 
Payne  Female periodontal maintenance Greater ABL, crestal and subcrestal 2-year longitudinal  
  patients within five years of   density bone loss in the osteoporotic clinical study 
  menopause; 21 with normal BMD and estrogen-deficient women 
  and 17 osteoporotic women  
Reinhardt et al. Women within five years of  Non-smoking osteopenic/  2-year prospective 
  menopause, 59 with adult  osteoporotic periodontitis patients longitudinal study 
  periodontitis and 16 non-periodontitis. with estrogen deficiency had more 
  Stratified by serum estradiol levels bleeding on probing and clinical  
       attachment levels 
Hildebolt et al. 135 postmenopausal women  Attachment loss was correlated with Cross-sectional 
  aged 41-70 years, no moderate or tooth loss but not with BMD 
  severe periodontitis 
Streckfus et al. 28 healthy women, ages 23-78 More ABL, more missing teeth, in  Cross-sectional 
      postmenopausal women on estrogen 
      therapy than in premenopausal women 
von Wowern et al.  12 women with osteoporotic  Osteoporotic subjects had more loss  Cross-sectional 
.  fractures    of attachment than normal subjects 
Elders et al. 216 females between 46 and 55 No significant correlation was  Cross-sectional 
      observed between probing depth, 
      bleeding on probing, missing teeth, 
      alveolar bone height, and bone mass  
 
 In the research by Elders and colleagues (1992), lumbar bone mineral density and metacarpal 
cortical thickness were compared to alveolar bone height measured on bitewing radiographs, and to 
clinical parameters of periodontitis. No significant relationship was observed between the bone mass 
measurements and alveolar bone height, or the periodontal parameters. The mean age in this group was 
relatively young, between 46 and 55 years of age, and the sample size was very small, which could have 
contributed to the lack of correlation. Similar findings were reported in a study of tooth loss and 
attachment loss when related to vertebral and proximal femoral bone mineral density. One-hundred-
thirty-five (135) women with at least ten teeth and no evidence of moderate or severe periodontal disease 
were examined. Attachment loss correlated with tooth loss but not with vertebral or proximal femur bone 
density (Looker1997). In an age cohort of 70-year-old women, fifteen subjects with osteoporosis were 
compared to twenty-one subjects with normal bone mineral density. No statistically significant 
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differences were found in gingival recession or marginal bone level between the women with osteoporosis 
and the women with normal bone mineral density (Jeffcoat 2001). 
 In contrast to these reports, other authors have noted a significant relationship between systemic 
osteopenia and periodontal bone loss. Von Wowern and colleagues (1994) found greater amounts of loss 
of attachment in osteoporotic women, in a small population with a mean age of 68. Osteoporosis was 
assessed using the bone mineral content of the mandible and forearm determined by dual photon 
scanning. 
 In a two-year longitudinal clinical study, alveolar bone height and bone mass density changes 
were studied in seventeen osteoporotic/osteopenic women, compared with twenty-one women with 
normal lumbar spine bone mineral density. Osteoporotic women exhibited a higher frequency of alveolar 
bone height loss and crestal and subcrestal density loss relative to women with normal bone mineral 
density (Payne 1999). 
 Fifty-nine moderate/advanced adult periodontitis patients and sixteen non-periodontitis subjects, 
all within five years after menopause at baseline, were stratified based on serum estradiol levels. 
Attachment loss was assessed over a two-year period and correlated to bone mineral density and serum 
estradiol levels. Serum estradiol levels did not influence the percentage of sites losing attachment for 
either the periodontitis or the non-periodontitis groups. The estradiol-deficient group had a trend toward a 
higher frequency of sites with attachment loss>2 mm. Larger prospective longitudinal studies are needed 
to further evaluate osteoporosis as a risk factor for periodontal disease (Reinhardt et al. 1999). 
 Research conducted by the author and colleagues (Famili et al. 2005) concluded that there was 
little evidence of an association between periodontal disease and longitudinal changes in bone mineral 
density, but there was significant association between tooth loss and change in bone mineral density. 
 Cross-sectional studies have limitations. No information relevant to the diseases studied is 
available prior to the date of the exam. Although both osteopenia and periodontal disease are chronic 
diseases and can be assumed to have been present prior to the observations, most of the studies adjust 
only for age and do not consider other risk factors. Another common deficiency among these studies is 
that the sample size is usually too small to make definite associations between periodontal disease and 
osteoporosis as measured by using bone mineral density.  
 
 22
 
 
1.3 THE RELATIONSHIPS AMONG OSTEOPOROSIS, BONE LOSS, AND 
PERIODONTAL DISEASE IN MEN GENERALLY AND IN MEN WITH PROSTATE 
CANCER UNDER ANDROGEN DEPRIVATION THERAPY 
 
 
1.3.1 Osteoporosis in men 
Bone loss occurs more gradually and at a later age in men with idiopathic age-related bone loss. This 
speaks directly to the issues of our current research, and in Table 1.5 we outline the published cross-
sectional and longitudinal studies performed in men with prostate carcinoma who were treated with 
androgen deprivation therapy. These men, on average, have bone mineral density measurements that are 
6.5-17.3 percent lower when compared with bone mineral density measurements in eugonadal men who 
are treated without androgen blockade. The duration of androgen deprivation therapy affects bone mineral 
density values significantly. In longitudinal studies, a 5.7-8.5 percent decrease in lumbar spine cancellous 
bone mineral density was revealed (using QCT) and a 1.8-2.3 percent decrease in femoral neck bone 
mineral density (using DXA) was recorded after twelve months of androgen deprivation therapy. 
 Men with prostate carcinoma who are treated with androgen deprivation therapy are elderly and 
are at risk for a wide variety of metabolic bone problems. Although some increase in the rate of bone loss 
may occur after the age of 50 years, this increase is not as rapid as that observed in women around the 
time of menopause (Warming 2002). Longitudinal studies have shown the rate of cortical bone loss in 
men to be approximately 0.5 percent to 1 percent per year in later life (Seeman 1995). The loss of 
cancellous bone, on the other hand, tends to proceed more rapidly (Mazess 1982 and 1990), which is 
reflected in an increasing incidence of spine and hip fractures in elderly men, particularly after the age of 
75 years (again, Seeman 1995, 1997, 2001). 
 Data on bone loss in otherwise healthy elderly men is sparse. Even less information is available 
concerning bone loss, fracture and mortality in men with additional risk factors for bone loss. Peak bone 
mass is higher in men than women because men have bigger bones. Peak bone mineral density is the 
same (Seeman 1997). The amount of trabecular bone lost at the spine and iliac crest during aging is 
similar in men and women. Cortical bone loss is less in men because endocortical resorption is less and 
periosteal formation is greater. Bone fragility is less in men because the cross-sectional surface of the 
bone is larger; because trabecular bone loss is less as a percentage of the higher peak bone mass; because 
trabecular bone loss occurs by thinning rather than perforation; and because periosteal appositional 
growth compensates for endocortical resorption by maintaining the bending strength of bone (again, 
Seeman).  
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 [Seeman (1999) even is capable of presenting data regarding racial differences in the fragility of 
bone, in addition to gender differences in fragility. Blacks have shorter vertebrae than whites, but 
vertebral width is similar. Trabecular thickness is greater in blacks than whites. Men have wider long 
bones than women. Blacks have wider long bones than whites. He summarizes the issue by saying that 
racial differences in vertebral strength are likely to be bone mineral density-, not size-, dependent. Greater 
periosteal expansion during growth in males than females, and in blacks than whites, establishes the 
gender and racial differences in peak bone size.] 
 The higher mortality rate (one-third greater) associated with hip fracture in men (Seeman 1995) 
compared with women may in fact be due to the frequent presence of underlying medical conditions or 
risk factors, such as a slow decrease in serum-free testosterone, alcoholism, tobacco use, hypogonadism, 
and disorders of calcium and Vitamin D absorption or metabolism. In one case control study, 
approximately a third of the men studied had a significant underlying condition that could affect calcium 
or bone metabolism (Seeman 1995, 2001; Deng 2004). Seeman (1997) sums up the risk factors for 
fracture in men by citing the age-related decline in testosterone, adrenal androgens, growth hormone, and 
insulin-like growth factor 1. Men with vertebral fractures often have hypogonadism or other illnesses with 
what Seeman calls suspiciously few clinical features---alcoholism, myeloma, malabsorption, primary 
hyperparathyroidism, haemochromatosis, and Cushing’s disease. 
 [In 2004, conceding that the single most important consideration in the treatment of osteoporosis 
is the individual’s absolute risk of fracture, Seeman considered what was out there that worked in the 
treatment of osteoporosis. Reported to reduce vertebral fractures are the bisphosphonates, raloxifene, 
parathyroid hormone, and strontium ranelate. The bisphophanates and hormone replacement therapy have 
been used to reduce fractures in one population of women, but hormone replacement is clearly not 
recommended (the discussion above). Calcium plus Vitamin D and the mechanical device of hip 
protectors reduced fractures in one study of the institutionalized elderly. Seeman saw little evidence to 
support treatment with calcitonin, fluoride, anabolic steroids, or active Vitamin D metabolites, and could 
only recommend lifestyle changes to maintain lifetime bone strength, not statistically reduce fracture 
risk.] 
 
1.3.2 Bone loss in men with prostate cancer 
There has been a gradual increase in the incidence of prostate cancer around the world since the 1960s. 
Prostate cancer occurs in older men and, as previously mentioned, aging is associated with bone loss in 
the range of 0.5 percent to 1 percent per year (Higano 2003, Mazess 1982). Decreased testosterone levels 
and hypovitaminosis D also occur in this population (Simon 2002, Higano 2003). These factors may help 
explain why osteopenia may be present in 10 percent to 25 percent of men with prostate cancer even 
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before androgen deprivation therapy is begun. While androgen deprivation therapy is an effective 
measure to control advanced prostate cancer, the development of osteoporosis in patients treated with 
androgen deprivation therapy has not aroused general attention until recent years (Wei et al. 1999; 
Diamond 1998; Morote et al. 2003; Deng 2004). Ross and Small indicated very recently (2002) that 
osteoporosis was an important and debilitating side effect of androgen deprivation therapy, but the precise 
estimates of its incidence and importance have not yet been made fully clear. 
 
1.3.3 Osteoporosis in men with prostate carcinoma under androgen suppression therapy  
*The literature regarding this subject is summarized as Table 1.5, below. 
Prostate carcinoma is the most common visceral malignancy and the second leading cause of death from 
cancer in men (Greenlee 2001). Androgen deprivation therapy is the recommended treatment for men 
with metastatic or locally advanced, non-metastatic prostate carcinoma (Stoch et al. 2001). Although it 
has been demonstrated that this form of therapy significantly reduces tumor growth and improves survival 
beyond three years after completion of the androgen deprivation therapy, there is growing concern 
regarding the negative effects of androgen deprivation therapy on the skeleton. Accelerated bone loss 
(Higano 2003), osteoporosis, and a potential for increased fracture rates have been reported in men with 
prostate carcinoma who are receiving androgen deprivation therapy. Because many patients who present 
with prostate carcinoma are elderly and may have pre-existing osteoporosis, sub-clinical Vitamin D 
deficiency, or any of a multitude of medical problems, the risk of skeletal deterioration is increased 
(Simon 2002). At present the prevalence of osteoporosis in men under androgen suppression is not well 
known, and neither is the impact of the time spent under this treatment. 
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Table 1.5 Percent change in lumbar spine and hip bone mineral density (BMD) in men with 
prostate carcinoma receiving androgen-deprivation therapy 
                                                                                      Percent change in BMD per year 
                              
Study 
Number of 
Patients 
Treatment LS DXA LS QCT Hip DXA 
Mallefert1999 12 LHRH agonist -4.6 _ -3.9 
Daniell 2000 16 Orchiectomy/LHRH agonist _ _ -2.4 
Higano1999 18 CAB -4.5 - -2.5 
Diamond 1998 12 CAB _ -6.6 -6.5 
Smith 2001 21 CAB -3.3 -8.5 -1.8 
Diamond 2001 21 CAB _ -5.7 -2.3 
Smith 2003 51 LHRH agonist/ CAB -2.2 _ -2.8 
Mittan 2002 15 CAB -2.8 _ -3.3 
Berruti 2002 42 LHRH -2.3 _ -0.5 
 
Footnote: 
Table 1.5 outlines the published cross-sectional and longitudinal studies performed in men with prostate 
carcinoma who were treated with androgen deprivation therapy (ADT). On average, these men have 
BMD measurement that are 6.5-17.3% lower compared with BMD measurement in eugonadal men who 
are treated with androgen blockade. The duration of ADT affects BMD values significantly. In 
longitudinal studies, a 5.7-8.5% decrease in lumbar spine cancellous bone mineral density was shown 
(using QCT) and 1.8-2.3% decrease in femoral neck BMD. 
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1.4 THE RELATIONSHIP OF PERIODONTAL DISEASE IN MEN WITH 
PROSTATE CANCER UNDER ANDROGEN DEPRIVATION THERAPY. A 
BRIEF SUMMARY PREFACE TO THE SUBSEQUENT CHAPTERS 
 
The relation of periodontal disease and osteoporosis due to androgen ablution is not well 
established. Studies to evaluate the relationship between osteoporosis due to androgen deprivation 
therapy and periodontal disease are essential for enhancing our understanding of systemic bone 
pathogenesis. There is no literature on the association between periodontal disease and prostate 
cancer under androgen deprivation therapy. 
 To address whether the two diseases are linked, we will analyze two data sets. In the first 
analysis, we will test the hypothesis that older women with periodontal disease will experience 
faster rates of bone loss (Chapter Two).  
 The second analysis will involve men undergoing androgen deprivation therapy for 
prostate cancer. These men have been enrolled in Bone loss in men with prostate cancer treated 
with androgen deprivation therapy (Susan L. Greenspan, MD, principal investigator), which is 
testing the hypotheses (1) that androgen deprivation therapy in men with prostate cancer is 
associated with a rapid increase in bone resorption and bone loss, as well as a change in body 
composition; and (2) that androgen deprivation in men with advanced prostate cancer therapy is 
associated with progressive loss of bone and lean body mass compared to normal controls; and 
(3) that bone resorption, bone loss, and general bone health will be further altered by additional 
systemic or local therapy for prostate cancer. As part of the current research, we will add a 
periodontal assessment and will test the additional hypothesis (4) that men with prostate cancer 
undergoing androgen deprivation therapy with have a higher prevalence of periodontal disease 
(Chapter Three).  
 Finally, we will examine the correlation between measures of bone mineral density and 
bone turnover to the existence of periodontal disease in this population of older men (again, 
Chapter Three).  
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2.1 Abstract of the research 
 
Purpose:  Previous cross-sectional studies have suggested a link between periodontal disease and 
osteoporosis. The purpose of the present study is to evaluate the association between changes in bone 
mineral density (BMD) and clinical signs of periodontal tissue destruction and tooth loss over a two-year 
period. 
Methods:  A total of 398 women (mean age 75.5 years) were randomly selected for an ancillary study of 
periodontal disease. We evaluated osteoporosis in association with the presence or absence of teeth, and 
further evaluated osteoporosis in association with periodontal disease. All subjects were participants at the 
Pittsburgh Clinical Center for the Study of Osteoporotic Fractures (SOF), a prospective cohort study of 
women 65 years+ designed to determine risk factors for fractures. Oral health examinations, including 
periodontal probing and attachment loss, were performed at the fourth clinical visit, on average six years 
after baseline. BMD of the total hip and its sub-regions were measured using dual energy X-ray 
absorptiometry at the time of dental examination, and two years later. Results are expressed as annual 
percentage change. 
 
Data analysis:  Generalized linear models were used to assess the association between BMD and the 
presence or absence of teeth and periodontal health status. Periodontal variables among dentate women 
included average loss of periodontal attachment (LOA); the number of sites with at least four millimeters 
(4mm) of attachment loss; and the presence or absence of calculus. 
 
Results:  A total of 145 (36.4 percent) women were edentulous and 163 (80.7 percent) had periodontal 
disease. Dentate women reported higher education (p<0.001), and a higher calcium intake (p=0.002). 
Absolute BMD and percentage change in BMD were similar in dentate and edentulous women. We found 
no difference in BMD, or in absolute or percentage change in BMD between women with or without 
periodontal disease. 
 
Conclusion:  Little evidence exists for an association between edentulousness, periodontal disease, and 
longitudinal changes in BMD.
 39
2.2 Background and rationale for the research 
Osteoporosis is a systemic skeletal disease characterized by low bone mass and micro-architectural 
deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. 
Osteoporosis is a major public health problem that most often affects postmenopausal women. 
 In the United States osteoporosis affects more than 25 million people, and predisposes patients to 
more than 1.3 million fractures annually (Annals of Periodontology Consensus Report 1996). Since 
alveolar bone loss is a clinical feature of periodontal disease, disturbances in bone metabolism and 
decreases in the bone mineral density (BMD) of the skeleton, especially in the jaws, may be a factor in 
periodontal disease (Wactawski-Wende et al. 1996). Osteoporosis and periodontal disease lead to 
significant morbidity, mortality, and expense. 
 The clinical importance of generalized bone loss as a contributor to alveolar bone loss and 
subsequent tooth loss is unclear. To date, the evidence for an association between tooth loss and bone 
mineral density (BMD) in the extra-cranial skeleton has been derived from cross-sectional studies, and 
results have been inconclusive (Tezal 2000). Several large studies conducted in early postmenopausal 
women failed to find significant associations between tooth status and BMD. Elders (1992) found no 
relationship between the number of missing teeth and either spine BMD or metacarpal thickness. Krall et 
al. (1996) conducted a longitudinal study on associations between tooth loss and bone loss in whole 
bodies, in the femoral neck, and in the spine, including 189 healthy white dentate postmenopausal women 
who participated in three intervention trials conducted within a seven-year period. Forty-five women (24 
percent) reported having lost one or more teeth. The rates of BMD changes at all three sites (whole body, 
femoral neck, spine) were independent predictors of tooth loss in the multivariate models, supporting a 
role for systemic bone loss in the development of tooth loss among postmenopausal women. 
 Bando et al. (1998) suggested that sufficient masticatory function with periodontally healthy 
dentition may inhibit or delay the progress of osteoporotic changes in skeletal bone, or that edentulous 
women may be more susceptible to osteoporosis. The role of osteoporosis or osteopenia in the etiology of 
periodontal disease is not fully understood. Observational studies support the possible role of low skeletal 
BMD or osteoporosis as risk indicators for reduced alveolar crestal height (Wactawski-Wende et al. 
1996). Ronderos et al. (2000) studied the possible association of periodontal disease with femoral bone 
mineral density (BMD) in a large sample of U.S. adults (n=11,655). Their finding indicates that, in the 
presence of high calculus scores, females with osteoporosis are at an increased risk for attachment loss. 
 In our earlier report (Weyant et al. 1999), we found no association between BMD and periodontal 
disease. However, no longitudinal studies have been reported to date. One intent of the present study was 
to extend the earlier report (Weyant et al. 1999) and evaluate the link between changes in bone mineral 
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density and clinical signs of periodontal tissue destruction. In addition, we examined the association of 
between edentulism and changes in BMD. 
 
2.3 The design/setting/patients and the materials and methods of the research 
A total of 398 women (mean age 75.5 years) were randomly selected for an ancillary study of periodontal 
disease, presence or absence of teeth, and osteoporosis. All subjects participated in the Pittsburgh Clinical 
Center for the Study of Osteoporotic Fractures (SOF), a prospective study of a cohort of elderly women 
>65 years of age at baseline, to determine risk factors for fractures. 
 From September 1986 to October 1988, a total of 2,401 women who were at least 65 years of age 
or older were recruited for the SOF from the Monongahela Valley near Pittsburgh, Pennsylvania. Age-
eligible women were identified on voter registration lists for zip codes within a 25-mile radius of 
Monessen, Pennsylvania. To be eligible to participate in this ancillary study, women had to be willing to 
continue participation in the SOF study, willing to have a dental examination, and willing to voluntarily 
sign a University of Pittsburgh Institutional Review Board (IRB)-approved consent form. Exclusion 
criteria for this study included presence of medical conditions that would preclude conducting an 
adequate oral examination. All women presenting for SOF examinations when the dentist examiner was 
present and who met the above eligibility criteria were eligible for enrollment into the dental study. 
BMD measurement 
Bone mineral density (g/cm) of the total hip and its sub regions (the femoral neck, the inter-trochanteric 
region, the trochanter) was measured using dual X-ray absorptiometry with Hologic QDR-1000 scanners 
(Hologic Inc., Waltham, MA). Bone mineral density of the calcaneus was measured with Osteo Analyzers 
(Siemens-Osteon, Wahiawa, HI) using single- photon absorptiometry at the baseline examination. Details 
of these measurement methods and densiotometry quality control procedures have been published 
elsewhere (Ensrud 1995). 
Periodontal assessment 
The assessment for periodontal destruction was made at three sites on the buccal aspect (mesiobuccal, 
midbuccal, distobuccal) of all remaining natural teeth (Weyant 1999). Only fully erupted teeth were 
measured. Loss of attachment was defined both clinically and quantitatively as the distance in millimeters 
(mm) from the cementoenamel junction (CEJ) to the base of the pocket. Probing depth was the distance 
from the free gingival margin (FGM) to the base of the sulcus/pocket. A woman was diagnosed with 
periodontal disease if she had more than three millimeters (>3mm) attachment loss (Weyant et al. 1999). 
Statistical analysis 
All data were screened for accuracy and completeness. SAS 8.2e™ software was used to analyze the data. 
Descriptive statistics were calculated for all variables including means, standard deviations, ranges and 
 41
percentages. Linear regressions were used to compare the rate of bone loss in edentulous vs. dentate 
women. Among dentate women, women with attachment loss >4 mm vs. women with <4 mm of 
attachment loss on more than twelve teeth were also compared. We initially adjusted for age. Multivariate 
adjusted models included variables known to influence bone density and fracture outcomes (age, weight, 
education, dietary calcium intake, alcohol use, walking for exercise). 
 
2.4 The results of the research, as described for this chapter 
Dentate vs. edentulous status of 398 women in the study was examined. Most (253) or 64 percent, were 
dentate, and 145 (36 percent) were edentulous. Dentate women were more likely to report a higher 
education, greater calcium intake, drinking alcohol and a dental examination in the last two-years 
compared with edentulous women. There were no differences in age, body weight, smoking, hormone 
use, and physical activity between the two groups. Similar proportions of dentate and edentulous women 
reported a history of fracture or osteoporosis. 
 For the most part there was no difference in age-adjusted BMD, absolute rates of bone loss, or 
percentage rate of bone loss between dentate and edentulous women for tooth loss at other sites. Further 
adjustments for age, weight, education, dietary calcium intake, drinking alcohol, and walking for exercise 
had little effect on these results. The rate of bone loss at the trochanter was somewhat greater among 
edentulous women (0.86 percent per year) compared to dentate women (-0.52 percent per year). 
Periodontal disease 
The majority (80 percent) of dentate women had some evidence of periodontal disease (Table 1.4). Women 
with periodontal disease were slightly older than women without periodontal disease (p=0.07), but all 
other characteristics were remarkably similar in the two groups. We found no difference in BMD, or in 
absolute or percentage change in BMD between women with and without periodontal disease (Table 1.4). 
 We also correlated several other measures of periodontal disease with BMD, including average 
periodontal attachment loss, number of sites with > 6 mm attachment loss, site with > 4 mm attachment 
loss, average number of sites with bleeding, calculus and probing depth. In general there was no 
association between periodontal disease and rate of bone loss. 
2.5 A discussion of the research, as described for this chapter 
The overall prevalence of edentulism in this population of older women was higher (36 percent) 
compared with the 23 percent edentulism rate reported for the U.S. population of women ages 70 to 74 
years as published in the NHANES III study. The higher prevalence observed in our study could have 
reflected a continued increase in edentulism with advancing age. The women in our study ranged from 73 to 84 
years in age. We found little evidence to support an association between osteoporosis and edentulism. 
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BMD and rate of bone loss were similar in these two groups even after adjustments for established 
correlating factor of edentulism. 
 Tooth loss has been observed to be related to bone density in the oral cavity in a limited number 
of studies. When interpreting results in various anatomic regions, it is necessary to remember that tooth 
loss is highly influenced not only by periodontal disease, but also by the local practices of the dental 
community, as well as other factors related to oral health. 
 The majority (80 percent) of dentate women had some evidence of periodontal disease (p=0.07). 
We found no statistically significant associations between periodontal disease variables (average 
periodontal attachment loss, average number of sites with bleeding, and average number of sites with 
calculus) and BMD at trochanter, inter-trochanter and femoral neck either cross-sectionally or 
longitudinally. This was true even after controlling variables for age, weight, and other important 
correlating factors. A possible explanation of our lack of an association between periodontal disease and 
BMD may be because our population was chronologically older, and were missing among them a large 
number of teeth. We have no information on the individual reasons for missing teeth. This edentulousness 
could be due to periodontal disease that occurred much earlier in the individual’s life. 
 Historical events such as tooth loss can alter the interpretation of the current status of their 
periodontal disease. Loss of several periodontally involved teeth can result in an improvement of 
periodontal summary scores such as average loss of attachment. Compared to the other NHANES III 
studies (Winn 1999; Slade 1999), average attachment loss for the U.S. population was reported to be 2.1 
mm, while our data for our population showed an average attachment loss\ of 2.49 mm. The major 
strengths of this current study are its large sample size and well-controlled measurement of variables, 
which could confound relationship with BMD. The sample is drawn randomly from a large population of 
community-dwelling women. 
Limitations 
Interpretations of the present study may be limited, since periodontal measures of bone such as 
subtraction radiography or Shei bone score measurement were not available. In addition, blinded dental 
examiners were only able to record a single assessment of periodontal measurements. 
Conclusion 
There was little evidence of an association between edentulousness, clinical and periodontal disease, and 
longitudinal changes in BMD in this population of older women. Future studies may be needed to 
longitudinally correlate periodontal disease and BMD over the same period. 
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Table 2.1. Characteristics of postmenopausal women with teeth and without teeth (N=398) 
Values are mean (SD), number (%), or median (range) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
$ = Analysis was performed log transformed variable 
Values are mean (SD), number (%). 
 
 
 Dentate  
(n= 253)  
Edentulus  
(n= 145) 
p-value 
Age (yrs) 75.9 (4.12) 78.8 (4.40) 0.741 
Height (cm) 158.0 (5.45) 157.3 (6.01) 0.239 
Weight (kg) 68.5 (12.69) 67.85 (11.82) 0.587 
BMI (kg/m2) 27.4 (4.80) 27.4 (4.55) 0.935 
Age at menopause (yrs) 47.2 (6.5) 46.8 (5.6) 0.523 
Smoking (n, %) 
   Past  
   Current 
 
75 (29.64) 
11 (4.35) 
 
47 (32.64) 
7 (4.86) 
 
 
0.503 
Education (n, %) 
 > 12 years 
 > 16 years  
 
145 (57.31) 
91 (35.97) 
 
103 (71.03) 
12 (8.28) 
 
 
<0.001 
Dietary Calcium Intake (mg/day)$ 500.82 (1.81) 411.13 (1.93) 0.002 
Calcium supplement use, n (%) 103 (40.71) 49 (33.79) 0.172 
Alcohol Drinking, n (%) 97 (38.49) 43 (29.66) 0.076 
Walking for exercise, n (%) 111 (43.9) 46 (31.7) 0.017 
Diabetes, n (%) 17 (6.72) 8 (5.52) 0.634 
Osteoporosis, n (%) 25 (10.00) 12 (8.39) 0.599 
History of Fracture since 50 years, 
n (%) 
114 (45.1) 67 (46.2) 0.825 
Maternal history of fracture, n (%)  53 (25.85) 23 (21.30) 0.371 
Thiozide use (n, %) 14 (17.00) 22 (15.17) 0.636 
Estrogen use (n, %) 
  Past 
  Current 
 
46 (18.47) 
18 (7.23) 
 
24 (16.78) 
8 (5.59) 
 
 
0.423 
Glucocorticoid use (n, %) 20 (7.91) 13 (8.97) 0.712 
Dental examination (n, %) 
 Less than 6 months 
 One year ago 
 Two years ago 
> 2 years ago 
 
177 (69.86) 
44 (17.39) 
12 (4.74) 
20 (7.91) 
 
12 (8.28) 
18 (12.41) 
23 (15.86) 
92 (63.45) 
 
 
 
 
<0.001 
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Table 2.2 Age- adjusted BMD and annualized per cent change in BMD by edentulous status  
 
 Dentate 
(n=253) 
Edentulous 
(n=145) 
p-value  
BMD (g/cm2)    
Total Hip  
Femoral Neck  
Intertrochanter 
Trochanter 
0.74 (0.01) 
0.63 (0.01) 
0.87 (0.01) 
0.57 (0.01) 
0.73 (0.01) 
0.63 (0.01) 
0.86 (0.01) 
0.56 (0.01) 
0.528 
0.729 
0.661 
0.401 
Absolute rate of change in BMD (mg/cm2,yr)   
Total Hip 
Femoral Neck 
Intertrochanter 
Trochanter 
-4.31 (0.55) 
-3.18 (0.57) 
-4.92 (0.71) 
-2.96 (0.54) 
-5.07 (0.73) 
-3.03 (0.75) 
-5.88 (0.94) 
-4.60 (0.71) 
0.408 
0.871 
0.415 
0.068 
Per cent rate of change in BMD (%/yr)   
Total Hip  
Femoral Neck  
Intertrochanter 
Trochanter 
-0.60 (0.08) 
-0.50 (0.09) 
-0.59 (0.08) 
-0.52 (0.10) 
-0.72 (0.10) 
-0.49 (0.12) 
-0.72 (0.11) 
-0.86 (0.13) 
0.343 
0.958 
0.325 
0.045 
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Table 2.3 Characteristics of women with and without periodontal disease (n=202) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Periodontal Disease ( > 4 mm)   
 Yes  
(n= 163)  
No 
(n= 39) 
p-value 
Age (yrs) 76.39 (4.25) 75.08 (3.67) 0.078 
Height (cm) 157.65 (5.11) 158.43 (5.88) 0.407 
Weight (kg) 68.01 (12.40) 69.33 (9.83) 0.539 
BMI (kg/m2) 27.37 (4.87) 27.71 (4.19) 0.690 
Age at menopause (yrs) 47.83(6.03) 46.02 (7.99) 0.118 
Current Smoking (n, %) 9 (5.52) 0 (0.0) 0.211 
Education (n, %) 
 > 12 years 
 > 16 years  
 
97 (59.5) 
54 (33.1) 
 
21 (53.9) 
16 (41.0) 
 
0.330 
Dietary Calcium Intake (mg/day) 484.91(1.81) 498.66(1.78) 0.796 
Alcohol Drinking, n (%) 61 (37.65) 14 (35.90) 0.839 
Walking for exercise, n (%) 71 (43.6) 15 (38.5) 0.563 
Diabetes (n, %) 9 (5.52) 1 (2.56) 0.691 
Osteoporosis (n, %) 15 (9.38) 5 (12.82) 0.521 
History of Fracture since 50 (n, %) 70 (42.9) 19 (48.7) 0.514 
Maternal history of fracture  32 (24.81) 14 (41.18) 0.059 
NSAID use (n, %) 38 (23.31) 9 (23.08) 0.975 
Current HRT use (n, %) 13 (7.98) 0 (0.0) 0.077 
Glucocorticoid use (n, %) 13 (7.98) 3 (7.69) 1.000 
Dental examination (n, %) 
 Less than 6 months 
 
 One year ago 
 Two year ago 
> 2 yrs ago 
 
119 (73.0) 
30 (18.4) 
6 (3.7) 
8 (4.9) 
 
31 (79.5) 
4 (10.3) 
1 (2.6) 
8 (4.9) 
0.564 
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Table 2.4 Age adjusted BMD and annualized percent change in BMD by periodontal status 
(N=202) (comments, n=51 not availed) 
 
 Periodontal Disease 
Yes (n=163)  
 
No (n=39)  
 P-value 
BMD (g/cm2)    
Total Hip  
Femoral Neck  
Intertrochanter 
Trochanter 
0.74 (0.01) 
0.63 (0.01) 
0.87 (0.01) 
0.56 (0.01) 
0.74 (0.02) 
0.63 (0.02) 
0.87 (0.02) 
0.57 (0.02) 
0.991 
0.839 
0.928 
0.931 
Absolute rate of change in BMD (g/cm2,yr)   
Total Hip 
Femoral Neck 
Intertrochanter 
Trochanter 
-4.17 (0.70) 
-2.76 (0.70) 
-4.48 (0.91) 
-2.76 (0.68) 
-3.94 (1.44) 
-3.08 (1.43) 
-4.50 (1.87) 
-3.45 (1.40) 
0.888 
0.844 
0.994 
0.657 
Percentage rate of change in BMD (%/yr)   
Total Hip 
Femoral Neck  
Intertrochanter 
Trochanter 
-0.54 (0.10) 
-0.42 (0.11) 
-0.53 (0.11) 
-0.47 (0.12) 
-0.59 (0.20) 
-0.50 (0.23) 
-0.65 (0.25) 
-0.58 (0.22) 
0.906 
0.756 
0.837 
0.504 
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3.1 Abstract of the research 
 
Purpose:  To test the hypothesis that men undergoing androgen deprivation (ADT) as treatment for 
prostate cancer are at greater risk of periodontitis and tooth loss.  
Materials and Methods:  Eighty-one (81) men with prostate cancer (mean age 68.5 years) were 
recruited among 325 enrolled in an osteoporosis study. Of these, 68 men were eligible to participate in 
this study.  The prevalence of periodontal disease among men with prostate cancer (n=41) undergoing 
androgen deprivation (mean years treated=1.5) was compared to men with prostate cancer not undergoing 
androgen deprivation (n=27, the controls). The prevalence of periodontal disease was examined in 
relationship to bone mineral density (BMD) among men with prostate cancer both with and without ADT.  
Outcome Measures:  A periodontist blinded to ADT status recorded probing depth; periodontal 
attachment loss; bleeding; Plaque Index; gingival recession; missing teeth; and calculus. Logistic 
regression models tested the association between ADT and periodontal disease. Linear regression 
models assessed the association between periodontal disease and bone mineral density among both groups 
with prostate cancer (treated/untreated). We adjusted for variables known to influence periodontal disease 
including age, race, smoking, history of periodontal disease. 
Results: The prevalence of periodontal disease was 80.5% (n=33) among men on ADT compared 
with 3.7% (n=1) among men not on ADT, odds ratio (95%confidence interval) =3.33(1.07-10.04). Men 
on ADT had significantly greater probing depth (p<0.001) and a higher plaque index (p<0.09). Eighty-
one men (76.9 %) undergoing ADT and the controls completed bone density exams. There was no 
relationship between bone mineral density and periodontal disease.  
Conclusions:  Men with prostate cancer undergoing ADT were more likely to have periodontal disease 
than men not on ADT. If confirmed in larger studies, this observation could have important public health 
implications given the increasing use of androgen deprivation therapy to treat prostate cancer. 
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3.2 Background and rationale for the research 
Carcinoma of the prostate is the most frequently diagnosed malignancy and the second leading cause of 
cancer death among men in the western world. The peripheral blockage of androgen action remains a 
critical therapeutic option in the treatment of prostate cancer. However, androgen deprivation therapy 
(ADT), the most effective systemic therapy for prostate cancer, is a major risk factor for male 
osteoporosis (Ross and Small 2002; Wei 1999; Diamond 1998; Morote 2003; Deng 2004). Androgen 
deprivation therapy causes increased osteoclastic activity (Higano 1983), bone resorption (Seeman 1997), 
and bone loss (Seeman 2004). Rates of bone loss ranged from 2 percent to 8 percent in the lumbar spine 
and from 1.8 percent to 6.5 percent in the femoral neck during the initial twelve months of continuous 
androgen deprivation therapy (Wei 1999; Higano 2003). An increased risk of fracture in men with 
prostate carcinoma who were treated with androgen deprivation therapy was also observed (Seeman 
1983). 
 Periodontal disease results in resorption of alveolar bone and loss of the soft tissue attachment to 
the tooth. There is biological plausibility that periodontal destruction may be adversely influenced by 
systemic bone loss (Rees 2003; Albandar 1990 and 2002; Slots 2003; Nunn 2003; Genco 1996). None of 
this previous research, however, has examined the link between androgen deprivation therapy with 
periodontal disease. The incidence of periodontal disease increases with advancing age, and current 
demographic shifts in the age distribution will lead to increases in the number of people with periodontal 
disease. 
 The purpose of the present study was to compare the prevalence of periodontal disease in men 
with prostate cancer receiving androgen deprivation therapy, with a control group of men with prostate 
cancer who were not receiving androgen deprivation therapy. In addition we examined the relationship 
between periodontal disease and measures of bone mineral density in these men. 
 
 
3.3 The design/setting/patients and the materials and methods of the research 
A total of 81 men (mean age 68.5 years) agreed to participate in this periodontal disease study. All men 
were recruited from a larger group of 325 ambulatory men participating in a study of bone loss in men 
with non-metastatic prostate cancer being treated with androgen deprivation therapy (ADT) or men not 
receiving androgen deprivation therapy. 
To be eligible for enrollment in the current ancillary research, the men had to be willing to submit 
to a comprehensive periodontal dental examination, and be willing to sign a University of Pittsburgh 
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Institutional Review Board (IRB)-approved consent form to participate in the current research. Exclusion 
criteria for this study were (1) the presence of medical conditions that preclude conducting an adequate 
oral examination, such as a history of heart disease or joint replacement or any medical disease that 
requires pre-medication with an antibiotic before a periodontal exam; (2) mental or legal incapacitation so 
that informed consent cannot be obtained; and (3) history or evidence of metabolic bone disease including 
hypercalcemia, hyperparathyroidism, Paget's disease of bone, osteomalacia, or osteogenesis imperfecta; 
and (4) hyperthyroidism or hypothyroidism recognized within six months of study enrollment. The total 
number of men excluded was 13 ( 11 edentulisum and two due to medical problem), leaving 68 men 
participating. 
Periodontal assessment 
A periodontist (PF), blinded to treatment status, completed comprehensive periodontal examinations 
[probing depth, clinical attachment loss, bleeding upon probing, Plaque Index, gingival recession, missing 
teeth, and calculus] on each subject. Probing depth was measured from the gingival margin with the use 
of a calibrated probe (HuFriedy Michigan 0 probe, diameter of probe is 0.5 mm, HuFriedy Chicago IL). 
Probing depth was measured on six sites per tooth (distobuccal, midbuccal, mesiobuccal, distolingual, 
midlingual, and mesiolingual). The loss of clinical attachment is defined as the distance, in millimeters 
(mm), from the cementoenamel junction (CEJ) to the base of the periodontal pocket. A subject was 
considered to have clinical presence of periodontal disease if he had more than 3mm or more of 
attachment loss (Weyant et al. 1999), as the definitive diagnostic marker. Probing depth is the distance 
from the free gingival margin (FGM) to the base of the sulcus/pocket. Gingival bleeding was coded as (0: 
no bleeding; 1: bleeding); supragingival plaque was coded (0: no plaque; 1: plaque), and calculus was 
measured as (0: no calculus; 1: supragingival calculus). All missing teeth were recorded on a standard 
dental form. History of periodontal disease, dental hygiene, frequency of tooth brushing, frequency of 
flossing, and visits to the dentist were also recorded (Weyant et al. 1999). 
BMD measurement 
Bone mineral density of the spine and hip was measured by using Fan-beam dual energy X-ray 
absorptiometry (DXA), using a QDR4500 A (Hologic, Inc., Bedford MA). Standardized procedures for 
patient positioning and scan analysis executed. A spine phantom was scanned daily and indicated no 
shifts or drifts in scanner performance.  
Statistical analysis 
Prior to statistical analysis, all data were screened for accuracy. Log Exact™ software was used to 
analyze the data. Descriptive statistics were calculated for all variables including mean, standard 
deviations, ranges, and percentages. Logistic regression models were used to compare the prevalence of 
periodontal disease vs. the absence of periodontal disease, and presented as odds ratios [OR] including 
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95% confidence intervals. Linear regressions were used to examine BMD and its relation to periodontal 
disease. 
All models were initially adjusted for age. Multivariable adjusted models included variables 
known to influence periodontal disease, specifically age, smoking, flossing, brushing, and visits made to 
the dentist and history of periodontal disease (Albandar 1990 and 2000; Slots 2003; Nunn 2003; Genco 
1996; Eggert 2001; Grossi; van Winkellhoff 2001) 
 
 
3.4 The results of the research, as described for this chapter 
Sixty-eight men were examined, including 27 men with prostate cancer not undergoing androgen 
deprivation therapy and 41 men with prostate cancer receiving androgen deprivation therapy for varying 
lengths of time. Eleven men (13.6 per cent) were edentulous and were counted among those thirteen 
individuals excluded from further analysis. The prevalence of edentulism did not differ between men 
undergoing androgen deprivation therapy and those men not undergoing androgen deprivation therapy. 
Completing the comprehensive periodontal exam was not possible on two subjects, due to their 
compromised medical condition, leaving 68 men for the final analysis. 
 The mean age of the men undergoing androgen deprivation was 70.5 years, and 68.5 years among 
men not undergoing androgen deprivation therapy (p=0.09). A higher proportion of men undergoing 
androgen deprivation therapy were 65 years of age or older (Table 3.1). There were no statistical 
differences in age, race, education, or smoking between the two groups. Three men among those 
undergoing androgen deprivation therapy (7.32 percent) had a history of periodontal disease extending 
two or more years in treatment, compared with eight percent of men not on androgen deprivation therapy. 
Although there were no differences in dental hygiene habits [brushing, flossing, visits to the dentist] 
between the men undergoing androgen deprivation therapy and those who were not, overall the men had 
excellent hygiene habits, with fifty percent brushing twice a day, and about sixty percent daily flossing. 
The bulk of the set (46 percent) visited the dentist regularly, at the recommended yearly intervals. Few 
men had any missing teeth or dental caries (p=1). Nevertheless, eighty-two percent (34 men) of the men 
undergoing androgen deprivation therapy had moderate plaque (p=0.09), and sixty-eight percent (28 men) 
had bleeding upon probing (p=0.001).  
Periodontal disease  
The majority of subjects receiving androgen deprivation therapy had evidence of periodontal disease. 
These and other indices of periodontal disease are summarized in Table 3.2. Among the 68 subjects, thirty-
three (33) men (80.95 percent) had periodontal disease compared to one man (3.75 percent) not receiving 
androgen deprivation therapy who had periodontal disease. Men receiving androgen deprivation therapy 
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had greater pocket depth (>3mm) and were more prone to attachment loss, recession, and tooth mobility. 
Tooth mobility was present in 14.4 percent of men undergoing androgen deprivation therapy, and not 
present in men who were not on androgen deprivation therapy (p=0.074). 
 In unadjusted models, the odds of developing periodontal disease were three-fold greater among 
men on androgen deprivation therapy compared with men not receiving androgen deprivation therapy 
(Table 3.3). Adjustments for age attenuated this association but it remained borderline significant. Further 
adjustments for smoking, race, and history of periodontal disease had little effect. 
We examined the relationship between periodontal disease and bone mineral density in these 
subjects. As shown in Table 3.4, bone mineral density was similar in both men with and without 
periodontal disease after adjusting for ADT.  
 
 
3.5 A discussion of the research, as described for this chapter  
We found that the prevalence of periodontal disease was about three times greater in the group 
undergoing androgen deprivation therapy compared with the group not receiving androgen deprivation 
therapy, even after we adjusted for age, race, smoking and history of periodontal treatment. To our 
knowledge this is the first report of a higher prevalence of periodontal disease in men on ADT. If 
confirmed in other larger studies, this observation could have major public health consequences given the 
increasing number of men with prostate cancer and the increasing use of ADT to treat these men. Many 
patients are now being diagnosed with early or progressive disease on the basis of a rising prostate-
specific antigen level alone, and hormonal therapy is being employed earlier in the course of the disease. 
As a consequence, many patients are being treated with hormonal therapy at the asymptomatic stage and, 
by virtue of the natural history of the disease, survive for years after diagnosis (Rashid and Chaudhary 
2004). Clinicians treating men with ADT need to be aware of the increased need for dental visits to 
identify periodontal disease at the earliest stages, before tooth loss occurs. 
 Although the majority of individuals in this group were highly educated, visited the dentist 
regularly, and had very good plaque control, they had periodontal disease. Investigators have previously 
demonstrated that androgen deprivation therapy causes severe bone loss and osteoporosis, and this may 
represent the underlying factor which contributes to a relationship between periodontal disease and ADT. 
Androgen deprivation therapy may enhance rapid bone loss around the teeth, and initiate or accelerate 
periodontal disease, despite good plaque control. This condition appears to parallel an aggressive type of 
periodontal disease in which bone loss will happen in a short period of time despite the presence of 
minimal plaque, and good plaque control. In the presence of androgen ablation therapy other as-yet-
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unknown elements may influence the impact of local factors like plaque that can cause or aggravate 
periodontal disease. 
 The collective data reported in most of the published cross-sectional studies investigating the 
relationship between periodontal disease and bone loss or bone turnover appears to indicate a relationship 
between systemic bone mineral density and oral bone mineral density, but the sample size on all these 
studies was very small and only one investigator (Jeffcoat 1998) adjusted for age. Generally, most 
researchers used differing populations and did not adjust for essential covariants such as smoking. The 
exception to this is Kribbs, studying both normal and osteoporotic women (1990), who showed twenty 
percent less mandibular density as measured by quantitative analysis of intra-oral radiographs. Our 
previous study found a correlation between tooth loss and diminished systemic bone mineral density 
(Famili.et.al 2005). The research is strongest among reports of oral bone loss in osteoporotic women. 
Interpretations of the present study may be limited since periodontal measures of bone density or 
loss, such as subtraction radiography or Shei bone score measurements, were not available to the 
investigators. Additionally the sample size was small. A larger sample coupled with longitudinal analysis 
is needed to confirm these findings. However, the current research is significant in that the impact of 
androgen deprivation therapy on periodontal disease has not been reported before.  
We conclude there is an association between periodontal disease and androgen deprivation 
therapy. This may be due to the osteoporotic bone loss among the group of men receiving androgen 
deprivation therapy although there was no significant correlation between periodontal disease and bone 
mineral density in our study. Additional studies utilizing a larger sample size and longitudinal analyses 
are necessary to definitively correlate periodontal disease and androgen deprivation therapy. If these 
associations can be confirmed by research conducted with larger sample sizes, this observation may have 
important public health implications. 
 
Funding for this research was made available, in part, through  the Osteoporosis Prevention and Treatment Center 
at the University of Pittsburgh, which receives support through the National Institutes of Health (K24 DK 062895-
01) and the General Clinical Research Center of the University of Pittsburgh Medical Center (M01-RR0056). 
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Table 3.1 
Characteristics of men with prostate cancer with and without undergoing anti-androgen 
therapy (n=68) 
 No ADT (n=27) ADT (n=41)                                            
p value for exact test 
Age (mean+/-st) 
<=65 5(22.22) 8(19.51) 
65-75 20(70.37) 21(51.22) 
75+ 2(7.41) 12(29.27) 
.098 
Race 
White 24(88.89) 38(92.68) 
Black 3(11.11) 3(7.320 
.675 
Education level 
High School 9(33.33) 14(34.15) 
College 8(29.63) 15(36.59) 
Beyond college 10(37.04) 12(29.27) 
.781 
Current smoker 
Yes 1(3.70) 3(7.32) 0.64 
Former smoker (N, %) 2(.20) 8(.80) 0.51 
Alcohol drinking (N, %) 27(39.71) 41(60.29) 0.41 
Heart disease 
No 26(96.30) 40(97.56) 
Yes 1(3.70) 1(2.44) 
1.000 
Kidney disease 27(39.71) 41(60.29)  
Brush teeth 
Once a day 5(18.52) 13(31.71) 
Twice a day 16(59.26) 20(48.78) 
.540 
More than twice a day 6(22.22) 8(19.51) 
 
Floss   
No 14(51.85) 24(58.54) 
 
 
Yes 13(48.15) 17(41.46) .625 
Visit DMD/DDS    
Every six months 12(44.44) 12(29.27) 
Every year 9(33.33) 19(46.34) 
 
 
For emergencies 2(22.22) 10(24.39) .461 
Missing teeth 
No 2(7.41) 1(2.44) 
Yes 25(92.59) 40(97.56) 
.558 
Caries 
No 26(96.30) 38(92.68) 
Yes 1(3.70) 3(7.32) 
1.000 
Wears dentures 
No 27(100.00) 40(97.56) 
Yes 0(0) 1(2.44) 
1.000 
Plaque 
Mild 20(74.07) 7(17.07) 
Moderate 7(25.93) 34(82.93) 
<.09 
Bleeding 
No 20(74.07) 13(31.71) 
Yes 7(25.93) 28(68.29) 
.001 
History of periodontal disease    
One year 27(100.00) 38(92.68) 
Two ore more years 0(0) 3(7.32) 
.271 
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Table 3.2.  
Periodontal disease characteristics of men with prostate cancer with and without androgen 
deprivation therapy  
 
 
 
 
Not receiving 
androgen deprivation 
therapy  
Receiving androgen 
deprivation therapy 
P value for exact test 
Periodontal disease  No   26(96.30) 8(19.51) 
Yes 27(3.70) 41(80.49) 
.006 
Pocket 
2-3 26(96.30) 0(0) 
3-4 1(3.70) 41(100.00) 
<.001 
Attachment loss 
No 25(92.59) 0(0) 
Yes 2(7.41) 41(100.00) 
<.001 
Recession present 
No 20(92.59) 4(9.76) 
Yes 7(7.41) 37(90.24) 
<.001 
Mobility present 
No 27(100.00) 35(85.37) 
Yes 0.00 6(14.63) 
.074 
 
 
 
Table 3.3 
Odds Ratio [OR] (95 percent confidence intervals) of periodontal disease by 
androgen deprivation therapy 
 
 
95% CI  Model 
order 
Adjustment 
by OR SE P Lower Upper 
p value 
1 No 
adjustment 3.333 1.927 0.037 1.073 10.352 0.037
2 Age 2.977 1.817 0.074 0.900 9.849 0.074
3 Age, race 3.149 1.956 0.065 0.932 10.640 0.065
4 Age, smoker 3.122 1.921 0.064 0.935 10.427 0.064
5 Age, race, 
smoking, 
history of 
periodontal 
treatment 3.201 1.991 0.061 0.946 10.835 0.061
 
 
 
 
 
 
 
 
Table 3.4
Bone mineral density in men with and without periodontal disease, adjusted for receiving 
androgen deprivation therapy 
 
 
 With 
periodontal 
disease 
Without 
periodontal 
disease 
p value for 
exact test 
(n undergoing androgen 
deprivation therapy) 
33(80.49) 8(19.51) .006 
Femoral neck BMD(g/cm2) .76(.15) .77(.12) .797 
Total hip BMD(g/cm2) .97(.16) .96(.14) .986 
Lumbar spine(g/cm2) 1.00(0.17) 1.05(0.16) .256 
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 4.0 SUMMARY AND CONCLUSIONS 
THE RELATIONSHIPS BETWEEN PERIODONTAL DISEASE AND BONE LOSS ON MEN WITH 
PROSTATE CANCER UNDER ANDROGEN DEPRIVATION THERAPY. A BRIEF SUMMARY ANALYSIS 
OF THE RESEARCH CONDUCTED, AND A DISCUSSION OF THE RELATED ISSUES, LIMITATIONS, 
AND CONCLUSIONS OF THE RESEARCH AND THE DISSERTATION 
 
 
Periodontitis is a multi-factorial disease with microbial dental plaque as the initiator (Genco 1996; Nunn 
2003). The manifestation and progression of periodontitis is influenced by a wide variety of determinants 
and risk factors, including subject characteristics, social and behavioral factors, systemic factors, genetic 
factors, the microbial composition of dental plaque, and others (Genco 1996; Nunn 2003; Slots 2003). If 
periodontitis is not treated, the disease will slowly progress and painlessly destroy the bone which 
supports the teeth. Untreated, the disease will eventually cause tooth loss. 
 Osteoporosis, or porous bone, is characterized by reduced bone mass and structural deterioration 
of bone tissue, leading to abnormal bone architecture, fragility of bone, and increased risk of fragility 
fracture, particularly of the hip, spine, and wrist. Osteoporosis is a major American public health threat---
as the first-ever Surgeon General’s Report on bone health and osteoporosis made clear with its release on 
October 14, 2004---and approximately 1.5 million Americans will suffer fragility fractures each year, 
including 300,000 hip fractures, approximately 700,000 vertebral fractures, 250,000 wrist fractures, and 
more than 300,000 fractures at other sites. Ten million Americans already have osteoporosis, and 34 
million more have low bone mass, placing them at risk for osteoporosis (Surgeon General’s Report 2004). 
Half of all women and one-quarter of men over 50 will have an osteoporosis-related bone fracture in their 
lifetimes. 
 The costs, the Surgeon General points out, are tremendous: A fracture can be the beginning of the 
deterioration of physical and mental health. Even among individuals who can remain independent, a 
fracture diminishes the quality of life. The Surgeon General estimates that approximately 20 percent of 
elderly individuals who suffer a hip fracture (the colloquial indicating fracture for osteoporosis) will die 
within a year of the fracture (2004). 
 In fact, as osteoporosis researchers Steven R. Cummings and Joseph Melton summed up in The 
Lancet in 2002, osteoporosis has clinical and public health importance only because of these fractures, 
causing disability and contributing to health care costs. 
 Osteoporosis in men has profound clinical implications (Seeman 2001 and 2004; Slots 2003). 
Osteoporosis is a significant health problem and contributor to disability and premature mortality among 
older men. Osteoporosis occurring in middle-aged and elderly men is commonly associated with alcohol 
abuse, smoking, immobilization, and medications. Estimated national direct expenditures (hospitals and 
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 nursing homes) for osteoporosis and related fractures are $18 billion each year (U.S. Surgeon General 
2004); men comprise one-third of all osteoporosis cases, and account for one-third of the national health 
care expense deriving from osteoporosis care. 
 The issue of the morbidity of osteoporotic hip fractures is addressed directly by research 
published just this year by the well-respected Swedish investigator John A. Kanis, who has made a career 
of evaluating the economics of osteoporosis (Johnell and Kanis 2005). Furthermore, Kanis and the 
equally well-respected Joseph Melton editorialize in the Journal of Bone and Mineral Research (June 
2005) about the meaning of the reported incidence of hip fracture trends on osteoporosis treatment, 
concluding that clinicians and the population may be paying better attention to controlling the causes of 
hip fracture risk (falls and fragility) and that specific programs of selective screening and aggressive 
treatment to prevent bone loss may really be able to reduce population fracture rates over the short term 
(Melton Kanis Johnell 2005). 
 The Surgeon General in 2004 called on health professionals to look for “red flags” clinically and 
in research that may indicate that an individual or a population is at risk for osteoporosis-related fracture. 
The relationship between periodontal disease and bone loss is obvious clinically to dentists; examining 
this relationship further led to the investigation of the relationship between periodontal disease and bone 
loss and men with prostate cancer who are undergoing androgen deprivation therapy. 
 The overall prevalence of edentulism in the population of older women that we researched 
(Chapter Two) was higher (36 percent), compared with the 23 percent edentulism rate reported for the 
U.S. population for women 70 to 74 years as published in the NHANES III study. The higher prevalence 
observed in our study could have reflected a continued increase in edentulism with advancing age. The 
women in our study ranged from 73 to 84 years in age. We found little evidence to support an association 
between osteoporosis and edentulism. Bone mineral density (BMD) and rate of bone loss were similar in 
these two groups even after adjustments for established correlating factors of edentulism. 
 Tooth loss has been observed to be related to bone density in the oral cavity in a limited number 
of studies. When interpreting results in various regions, it is necessary to remember that tooth loss is 
highly influenced not only by periodontal disease, but also by local practices of the dental community as 
well as other factors related to oral health. The majority (80 percent) of dentate women had some 
evidence of periodontal disease (p=0.07). We found no statistically significant associations between 
periodontal disease variables (average periodontal attachment loss, average number of sites with bleeding, 
and average number of sites with calculus) and bone mineral density at trochanter, inter-trochanter and 
femoral neck either cross-sectionally or longitudinally. This was true even after controlling for age, 
weight, and other important correlating factors. A possible explanation of our lack of an association 
between periodontal disease and bone mineral density may be because our population was older, and were 
 63
 missing a large number of teeth. We have no information on the reasons for missing teeth. This finding 
could be due to periodontal disease that occurred much earlier in a given subject’s life. Historical events 
such as tooth loss can alter the interpretation of the current status of any given subject’s periodontal 
disease. Loss of several periodontally-involved teeth can also result in an improvement of periodontal 
summary scores such as average loss of attachment. 
 Compared to the other NHANES III studies, where average attachment loss for the U.S. 
population was reported to be 2.1mm, our data showed an average attachment loss of 2.49mm. The major 
strengths of this study (again, Chapter Two) are its large sample size and well-controlled measurement of 
variables, which could confound relationships with bone mineral density. The sample is drawn randomly 
from a large population of community-dwelling women. 
 In our current research, studying the effects and relationships of periodontal disease and androgen 
deprivation therapy in men (Chapter Three), the overall prevalence of periodontal disease was very high 
in the group under androgen deprivation therapy even after we adjusted for age, race, smoking and history 
of periodontal treatment. Our review of the literature indicated that other comparisons between 
periodontal disease and androgen deprivation therapy have not yet been reported, so we cannot compare 
our findings to any others. 
 The majority of men under androgen deprivation therapy nevertheless had some evidence of 
periodontal disease (p<0.01). We found statistically significant associations between periodontal disease 
variables (these being average periodontal attachment loss, pocket depth, recession, average number of 
sites with bleeding, and plaque) and androgen deprivation therapy, that we have summarized as Table 3.2 in 
that chapter. These associations held true even after controlling for past history of periodontal treatment, 
age, race, and smoking  
 Although the majority of individuals in this group were highly educated, visited the dentist 
regularly, and had very good plaque control, they had periodontal disease because they were undergoing 
androgen deprivation therapy. As the original study of bone loss in men with prostate cancer (by 
Greenspan in 2004) demonstrated, undergoing androgen deprivation therapy causes severe bone loss and 
osteoporosis, and may also precipitate rapid bone loss around the teeth and the presence of periodontal 
disease, even with good plaque control. This situation creates a scenario similar to an aggressive type of 
periodontal disease in which bone loss will happen in a short period of time despite the presence of 
minimal plaque. In the presence of androgen ablation therapy, there may be other factors at work besides 
the influence of local factors like plaque that can cause or aggravate periodontal disease.
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 4.1 The limitations of the research 
The obvious empirical strength of our first study (Chapter Two) was its large sample size, drawn 
randomly from a large population of community-dwelling women, and its well–controlled measurement 
of variables. 
 We believe that the current research avenue (studying the effects and relationships of periodontal 
disease and androgen deprivation therapy in men (Chapter Three), is significant in that these observations 
have never been reported before. Only a limited amount of research relates osteoporosis in men to the 
presence of androgen deprivation therapy, and the authors believe that ours is the first empirical data 
relating the presence of androgen deprivation therapy to rapid bone loss around the teeth. 
 Interpretations of the first study were limited because measurement of bone loss around the teeth 
was not available, and we had only a single record of periodontal assessment. Interpretations of the 
present study may be also limited, since periodontal measures of bone density or loss, such as subtraction 
radiography or Shei bone score measurement, were not available to the investigators, and the sample size 
addressed here is admittedly small. A larger research sample and longitudinal analysis is necessary to 
confirm this finding. 
 
4.2 Conclusions, and future recommendations for research 
 
We found small evidence of an association between periodontal disease and longitudinal changes in bone 
mineral density in this older women population reported in Chapter Two; in the subsequent research 
reported here in men (Chapter Three), we conclude that evidence of a strong association between 
androgen deprivation therapy and periodontal disease exists in the corresponding male population. 
Additional studies utilizing a larger sample size and longitudinal analysis may be necessary to correlate 
periodontal disease and changes in bone mineral density due to androgen deprivation. 
 Considering the relationship among bone mineral density, osteoporosis, and periodontitis in men, 
it is known that men completing androgen ablation therapy for control of prostate cancer are at higher risk 
for osteoporosis. As androgen deprivation therapy is the recommended treatment for men with metastatic 
or locally-advanced non-metatstatic prostate carcinoma, and as prostate carcinoma is the most common 
visceral malignancy and the second leading cause of death from cancer in men, the relationship between 
androgen deprivation therapy and loss of bone mineral density is a matter of public health importance. 
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